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Summary 
Background: The use of PN therapy in patients living with incurable cancer is understudied, 
and there is a need for a stronger evidence base regarding this treatment in patients with 
incurable cancer.  
Aims: This study aimed to describe the following aspects of PN treatment in patients with 
incurable cancer: indications for PN, dosage of PN given and dosage according to estimated 
energy requirements, administration of PN, duration of PN, reason for discontinuation of PN 
and survival on PN. 
Methods: A retrospective medical chart review of patients with incurable cancer receiving PN 
at Haukeland University hospital from 2011 to 2018 was conducted. Data on patient 
characteristics related to the time before the start of and during PN treatment, administration of 
PN and dosages of PN, time of termination and reason for termination, were collected.  
Results: Data from 133 medical charts were included. Mean (SD) age was 64 (12,4) years 
and 61 (45.9%) were male. The most common types of cancer were upper GI (n=48, 36.1%), 
and colorectal (n=31, 23.3%), and 111 (83.5%) of the patients had metastases. The most 
frequent indication for start of PN was insufficient oral and/or enteral intake. Most of the 
patients received PN daily. Mean (SD) estimated energy intake was 33 (6) kcal/kg/day. Median 
(Q1-Q3) start dose was 1000 (570-1100) kcal/day. Median highest dose received was 5 kcal/kg 
lower than estimated energy needs. Median (Q1-Q3) duration of treatment was 44 (18-99) days. 
Median (Q1-Q3) survival from start of PN was 81 (41-159) days. There was a positive 
correlation between duration of PN and survival from PN start, correlation coefficient rs=0.751, 
p<0.0005. 
Conclusion: The findings indicate that PN therapy in patients with incurable cancer was 
distributed across the population in terms of dosages, duration and survival. Most of the patients 
receive less than estimated energy needs from PN. Patients receiving PN for a longer period of 
time also survive longer. Discontinuation of PN was based on expected survival, complications 
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Cancer is a leading cause of mortality worldwide, responsible for 9.6 million deaths and 18.1 
million new cases in 2018 [1]. The development of better tumour-directed treatments and 
multiple treatments as standards have resulted in more people living with metastatic disease 
and advanced cancer [2]. The 5-year prevalence of cancer worldwide was in 2018 estimated to 
be 43.5 million, and cancer is the second leading non-communicable disease in the world [2, 
3]. In Norway, there were 34 190 new cases of cancer in 2018. More than 280 000 individuals 
are living with a cancer diagnosis or have previously had cancer. Due to an increasing life 
expectancy and a growing population, the number of cancer cases is expected to keep 
growing [4].  
Staging of the cancer is used to decide treatment options, assessment of prognosis, and for 
comparing treatment outcomes. The tumour-node-metastasis classification system is a 
commonly used tool where the cancer is described based on the size of the primary tumour, 
number of nearby lymph nodes affected, and absence or presence of distant metastasis [5]. 
Advanced cancer can be locally or metastatic. Locally advanced cancer describes cancer that 
has grown outside the organ it started but has not yet spread to distant parts of the body. The 
cancer is termed metastatic advanced cancer if the cancer has spread from the primary site to 
other parts of the body [6]. Cancer at an advanced stage where the cancer can no longer be 
treated is often referred to as incurable or end-stage cancer [7]. Patients with incurable cancer 
might receive cancer treatment or disease-directed therapy to prolong life and alleviate 
symptoms. An increasing number of people living with an incurable cancer diagnosis leads to 
more patients in need of palliative care [8]. 
1.2 Palliative care  
Palliative care aims to make life the best possible, both for the patient and relatives, in all stages 
of an incurable illness [7, 9]. The World Health Organization (WHO) defines palliative care as: 
an approach that improves the quality of life (QoL) of patients and their families 
facing the problem associated with life-threatening illness, through the prevention 
and relief of suffering by means of early identification and impeccable assessment 
and treatment of pain and other problems, physical, psychosocial and spiritual [10].  
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The main focus of palliative care is to prevent and alleviate symptoms and to help with 
spiritual/existential challenges and other difficulties the patient may have [11]. Anti-cancer 
treatment may be a part of the palliative care with an intention to prolong life and reduce 
symptoms [12]. Tailored palliative care aiming to reduce the number and severity of 
burdensome symptoms is considered as the best strategy to improve QoL in patients with 
incurable cancer [13]. It is recommended to introduce palliative care early in the disease 
trajectory, as it has shown to give better results in terms of survival, pain management, 
symptoms, and QoL [14-16]. 
Patients with incurable cancer often experience symptoms such as fatigue, pain, constipation, 
weakness, and anorexia, as a consequence of the disease and/or treatment. This may contribute 
to distress and diminish the patients' QoL [11, 13]. Other characteristics in patients with 
incurable cancer are weight loss, muscle wasting, and reduced physical function, making them 
prone to wasting conditions such as severe malnutrition, cachexia, and sarcopenia [17, 18]. 
 Cancer cachexia 
The wasting syndrome cancer cachexia is an adverse effect of cancer, associated with reduced 
physical function, reduced tolerance to anticancer treatment, and increased mortality [19]. The 
prevalence of cancer cachexia ranges from 50-80% in patients with incurable cancer [20, 21]. 
This leads to severe consequences both for the individual patient and for the health care system 
[22]. The international consensus from 2011 defines cancer cachexia as “a multifactorial 
syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat 
mass) that cannot be fully reversed by conventional nutritional support and leads to progressive 
functional impairment” [19]. Key characteristics of the cachexia syndrome are reduced 
nutritional intake, anorexia, systemic inflammation, and altered metabolism such as increased 
proteolysis and increased energy expenditure [19].  
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Figure 1. Three stages of cancer cachexia from Fearon et.al [19].  
Cancer cachexia can develop progressively through three stages: pre-cachexia, cachexia, and 
refractory cachexia (figure 1) [19]. Pre-cachexia is recognized by involuntary weight loss below 
5%, induced by metabolic change and anorexia. Factors such as cancer type and stage, the 
presence of systemic inflammation, reduced food intake, and lack of response to anticancer 
therapy impacts on the risk of progression to cancer cachexia [19]. Cancer cachexia is present 
when either weight loss exceeds 5% the last 6 months, or weight loss exceeds 2% along with 
either body mass index (BMI) < 20 kg/m2 or sarcopenia [19]. Refractory cachexia is likely to 
develop in very advanced cancers or by rapidly progressive cancer unresponsive to cancer 
therapy. This condition is characterized by a low performance score, a life expectancy of less 
than 3 months, and no response to anti-cancer treatment [19]. 
1.2.1.1 Inflammation in cancer cachexia 
The presence of a systemic inflammatory response is a major factor underlying nutritional and 
functional decline in cancer cachexia [23, 24]. The tumour releases inflammatory factors, 
including cytokines such as interleukin 1 (IL-1), IL-6, and tumour necrosis factor- (TNF-), 
which affect the brain, muscle, liver and fat function [25, 26]. These cytokines impact on the 
neuroendocrine control of appetite in the hypothalamus, resulting in anorexia and reduced food 
intake [25]. An imbalance between anabolism and catabolism, caused by the systemic 
inflammation, results in muscle wasting, with a decline in muscle mass and strength, and 
increased fatigue. The risk for cancer treatment toxicity is increased in cancer cachexia due to 
the stimulation of acute-phase protein production in the liver, which in turn leads to reduced 
drug clearance. Increased lipolysis and defective lipogenesis are caused by the cytokines, 
resulting in depleted energy stores in fat deposits [23, 27, 28].  
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The systemic inflammatory response alters the production of acute-phase protein in the liver, 
causing elevated C-reactive protein (CRP) levels and hypoalbuminemia [23]. These proteins 
can be used as specific biomarkers to assess the severity of the cancer-related systemic 
inflammation, alone or in combination, known as the Glasgow Prognostic Score (GPS) [23, 
24]. The GPS provides a score based on the presence of hypoalbuminemia (≤35 g/L) and 
elevated CRP (>10 mg/L). Both hypoalbuminemia and elevated CRP provides a score of 2. If 
only one of the factors is abnormal, the score is 1. The score is 0 if neither of the factors are 
abnormal [24]. “The GPS was modified, termed mGPS, to reflect the observation that 
hypoalbuminemia without an elevated CRP concentration was rare and that hypoalbuminemia 
on its own was not associated with poor survival” [24]. A modified Glasgow Prognostic Score 
(mGPS) combines the indicators of decreased plasma albumin and elevated CRP (Table 1) [24]. 
An elevated mGPS has been associated with poor survival in patients with cancer [24].  
Table 1. The Glasgow Prognostic Score and modified Glasgow Prognostic Score, from McMillan [24]. 
The Glasgow Prognostic Score (GPS) Points allocated 
CRP ≤10 mg/L and albumin ≤35 g/L 0 
CRP >10 mg/L 1 
Albumin <35 g/L 1 
CRP >10 mg/L and albumin <35 g/L 2 
  
The modified Glasgow Prognostic Score (mGPS)  
CRP ≤ 10 mg/L and albumin ≥35 g/L 0 
CRP > 10 mg/L 1 
CRP >10 mg/L and albumin <35 g/L 2 
CRP=C-reactive protein 
 Performance status 
A decline in physical function is frequently seen in patients with incurable cancer as the cancer 
advances [29] and leads to reduced independence, affects the possibility to self-expression and 
increase the need for care [30]. One way of measuring physical function, often referred to as 
performance status (PS) is by objective methods assessed by health care providers´ perception 
of what a patient can do [31]. Performance status is related to survival, need for services and 
may help predict the ability to tolerate treatments [32]. The Eastern Cooperative Oncology 
Group (ECOG)/WHO Performance Scale is a tool often used to evaluate performance status in 
clinical practice and research [31, 33, 34]. In the ECOG performance scale, the score ranges 
from 0 to 5 where a score of 0 indicates normal activity. A score of 4 denotes completely 
disability and a score of 5 indicates death, as shown in Table 2 [34].  
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Table 2. ECOG performance status scale [34].  
Grade ECOG performance status 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light housework, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up 
and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
ECOG=Eastern Cooperative Oncology Group. 
 Malnutrition  
Weight loss and malnutrition in advanced cancer are associated with increased morbidity and 
mortality, reduced QoL, physical function and tolerance to anticancer treatment [22, 23]. 
Malnutrition results from lack of intake and/or uptake and utilization of nutrients, leading to 
altered body composition and reduced physical and mental function [35]. Malnutrition is 
divided into three categories, based on the aetiology: disease-related malnutrition with 
inflammation, disease-related malnutrition without inflammation and non-disease related 
malnutrition [36]. Malnutrition without disease can be related to starvation, socioeconomic or 
psychological factors [36]. Disease-related malnutrition with inflammation is a condition that 
results from the activation of systemic inflammation by an underlying disease. “The 
inflammatory response causes anorexia and tissue breakdown, resulting in significant loss of 
body weight, alterations in body composition and decline in physical function” [36]. Disease-
related malnutrition with inflammation is subdivided into chronic disease-related malnutrition 
and acute disease-related malnutrition [36].  
The Global Leadership Initiative on Malnutrition (GLIM) describes a two-step approach for 
diagnosing malnutrition [37]. The first step is screening to identify every patient at risk of 
malnutrition by the use of a validated screening tool. The second step includes an assessment 
of clinical signs and causes for the patients identified at risk for malnutrition. A patient is 
assessed as malnourished with the presence of at least one phenotypic (non-volitional weight 
loss, low body mass index (BMI), reduced muscle mass) criterion and one aetiologic (reduced 
food intake or assimilation, malabsorption, disease burden/inflammatory condition) [37]. The 
severity of the malnutrition condition is determined based on the phenotypic criterion and 
divided into 2 categories: moderate or severe malnutrition [37].  
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1.3 Nutrition in patients with incurable cancer 
Life expectancy in patients in a palliative care setting may vary from months to years, making 
them a heterogeneous group regarding anticancer treatment, symptom burden and nutritional 
challenges [22]. Weight loss is a frequent characteristic associated with impaired performance 
status, reduced tolerance to anticancer treatment, shortened survival and reduced QoL in these 
patients [22, 23]. The aetiology of cancer-related weight loss is complex, including anorexia 
and reduced food intake, reduced uptake of nutrients or cancer cachexia, alone or in 
combination [19, 22, 23]. Anti-cancer treatment can affect GI and induce nutritional related 
symptoms such as nausea, vomiting, abdominal cramps, mucositis, paralytic ileus and 
malabsorption [38]. All of which can affect a patient’s appetite and food intake, resulting in 
weight loss and malnutrition. Nutritional care should be provided in a systematic sequence that 
involves distinct interrelated steps, called the nutrition care process (NCP) [36]. The NCP 
includes malnutrition risk screening, nutritional assessment, diagnostic procedure, nutritional 
care plan, nutritional therapy, monitoring and evaluating the effects of nutritional care and 
therapy, as well as documentation [36].  
1.4 Medical nutrition therapy  
Medical nutrition therapy includes oral nutritional supplements, enteral nutrition (EN) and 
parenteral nutrition (PN). It is called EN or tube feeding when the nutritional need is delivered 
to the gastrointestinal (GI) tract via a tube. Delivery of nutrients directly to the vein, intravenous 
feeding, is referred to as PN [36]. The term artificial nutrition has traditionally been used to 
describe EN and PN, but this term has been suggested replaced by medical nutrition therapy by 
the ESPEN guidelines recommendations on definitions and terminology of clinical 
nutrition [36].  
In cancer patients, medical nutrition is indicated if patients are unable to eat adequately [22]. 
No food intake for more than one week, or an estimated intake of less than 60% of requirement 
for more than 1-2 weeks, is considered as an inadequate nutritional intake [22]. Nutritional 
therapy is recommended to be offered step by step, from nutritional counselling to parenteral 
nutrition (PN) [22]. Interventions focusing on oral nutrition intake, such as counselling and oral 
nutritional supplements, are first-line in nutritional treatment. An inadequate oral nutrition 
intake despite intervention indicates the need for EN. In patients with chronic insufficient 
dietary intake were EN is not sufficient of feasible and/or if patients have uncontrollable 
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malabsorption, PN is recommended [22]. In some cases, there might be appropriate to skip 
some steps or start at a higher level of intervention [39].  
 Parenteral Nutrition 
Parenteral nutrition is intravenous administration of nutrients [36]. The term TPN is used if a 
patient receives nutrition exclusively from PN. Supplemental PN, partial PN or complementary 
PN refers to situations where PN is given in addition to EN or oral intake [36]. For patients with 
a functional GI tract, EN is preferable, but PN might be used as a supplement to EN or oral 
intake if it is not possible to cover a patient´s nutritional need via the GI tract [36]. When PN is 
given outside of the hospital, it is referred to as home parenteral nutrition (HPN) [36].  
1.4.1.1 Administration and composition of parenteral nutrition 
Parenteral nutrition therapy can be administered through a peripheral or central vein, depending 
on vein access, the duration of treatment, and the osmolarity of the PN solution. A peripheral 
venous catheter (PVC) might be used if treatment is assumed to last for less than 7 days. If 
treatment is estimated to last for more than one week, a central venous catheter (CVC) should 
be considered [39]. Careful patient evaluation, monitoring and planning of the PN treatment is 
necessary in order to avoid complications and side effects of the treatment [40].  
Parenteral nutrition solutions include macronutrients, water, electrolytes and 
micronutrients [36]. Carbohydrates, amino acids and lipids can either be administered 
separately, via a multi-bottle system or by using the all-in-one system [41]. The All-in-one 
system or multi-chamber bag system are mostly used in modern PN therapy and enables to 
infuse all daily needs for macronutrients, water, electrolytes and micronutrients from one 
bag [41]. Both standardized and individually compounded mixtures are available [39]. 
Standardized three-compartment bags, containing glucose, amino acids and lipids in separate 
chambers, are mostly used at hospitals in Norway. The solutions of nutrients in the different 
compartments are mixed immediately before administration and the addition of minerals, trace 
elements and vitamins is essential for the solution to be complete [39]. After mixing, the 
admixture should be administered within 24 hours.  
The administration techniques of PN treatment have improved during the past decades, with 
considerable changes regarding the dosage, composition and distribution of the PN 
macronutrients [12, 42]. Energy is provided by the glucose, lipids and proteins [43]. Proteins 
are provided by solutions of crystalline amino acids [36], including the essential amino acids 
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[44]. An adequate energy substrate is needed in order to optimize protein utilization, and it is 
recommended that the provision of non-protein energy should be 100-150 kcal [43, 44]. 
Glucose is the only substrate of carbohydrates used in PN solutions today [44]. It is 
recommended that glucose should be administered at 3-6 g/kg per day in order to avoid acute 
and long-term complications, such as hyperglycaemia, hypoglycaemia and overfeeding [43, 
45]. Hypercaloric PN practices in the early days of PN, aiming to reverse catabolism, 
particularly by the use of high glucose loads, have been replaced by more energy balanced PN 
solutions, after the integration of lipid emulsions [46, 47]. In long-term PN, the ratio of glucose 
to lipid is recommended to be between 70-85% from glucose and 15-30% from lipids [43].  
Fat provides energy and essential fatty acids. In the PN solution, fats are provided in the form 
of intravenous lipid emulsions (IVLE). Lipid emulsions are composed of triglycerides with 
phospholipids as emulsifiers. Oil which provides triglycerides is suspended in an aqueous 
dispersion consisting of phospholipid, glycerol and water. Formation of globules of 
triglycerides and phospholipids, structurally similar to chylomicrons, occur during mixing of 
the components [48]. Lipid emulsions have traditionally been based on soybean oil, which is 
rich in pro-inflammatory polyunsaturated fatty acids (PUFAs). Modern IVLE have replaced 
some of the soybean oil with coconut oil providing medium-chain saturated fatty acids, olive 
oil and fish oil, rich in anti-inflammatory n-3 PUFAs [49, 50]. Some oils are also used in a 
mixed IVLE. SMOFlipid®, which is a lipid emulsion composed of soybean oil, medium-chain 
triglycerides from coconut oil, olive oil and fish oil [49], is currently in use at Haukeland 
University hospital.  
In patients receiving PN as the only source of nutrition, multivitamins and trace elements should 
be added daily and monitored closely during treatment [51]. Multivitamin and mineral 
preparations added to the PN solution are designed to meet most of the patient´s needs. These 
levels may be inadequate in some situations, i.e. if there is a risk for refeeding syndrome, and 
additional individual supplementation might be required [52].  
 Parenteral nutrition in patients with incurable cancer 
The use of PN in patients with incurable cancer is a controversial subject due to conflicting 
evidence regarding its risks and benefits. There are large variations in its use worldwide, 
depending on ethical, medical and cultural considerations [53]. The ESPEN guidelines support 
PN in patients with incurable cancer who have failed oral and EN feeding and who have a life 
expectancy of longer than 2-3 months. However, the evidence supporting the beneficial effects 
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of PN is weak [12, 22, 54]. Before starting nutritional interventions in patients with incurable 
cancer, it is important to consider the cancer prognosis, expected benefits on QoL and potential 
survival, as well as potential burdens associated with the nutritional treatment [22]. “If expected 
survival is several months or years, nutrition therapy should be given with the aim to secure an 
adequate intake of energy and protein, to diminish metabolic disturbances, and to maintain an 
adequate performance status and subjective QoL” [23]. For patients with an expected survival 
from a few to several weeks, non-invasive interventions, primary aimed at psychosocial an 
existential support is recommended [23]. Medical hydration and nutrition are unlikely to 
provide any benefit for most patients in the terminal phase [22]. The ESPEN guidelines states 
that “there is little or no benefit from nutritional support in the last weeks of life, since it will 
not result in any functional or comfort benefit for the patient” [22]. The treatment is therefore 
recommended to be based on comfort and QoL and should be tailored to the patient´s 
symptomatic needs [23]. 
Early studies examining the effect of PN in patients with incurable cancer have failed to prove 
any positive benefits [12]. A meta-analysis from 1990, concluded that routine use of PN as well 
as research examining the effect of PN in patients receiving chemotherapy, should be strongly 
discouraged, due to potential harmful effects [55]. The conclusion from this meta-analysis [55], 
resulted in no randomised-controlled trials (RCTs) including patients with incurable cancer to 
be conducted for several decades [12]. The studies included in the meta-analysis were 
conducted in a period where PN therapy was given in hypercaloric amounts, with high glucose 
loads and infusion rates [12]. Composition of PN solutions, administration techniques and 
hygiene protocols has improved, making treatment safe [12]. Based on the evidence available, 







The overall aim of this study is to describe the current practice of PN therapy in patients with 
incurable cancer, receiving PN at Haukeland University Hospital, Bergen from 2011-2018. 
More specifically, the following research questions will be investigated: 
At start of PN: 
• What is the indication for start of PN? 
• What are the estimated energy needs and oral intake at start of PN? 
• How is PN administered?  
During PN: 
• What are the dosages of PN used at start and what is the highest dose? 
• How much of a patient´s estimated energy needs are provided by PN?  
• What is the duration of PN? 
Termination of PN: 
• What are the reasons for discontinuation of PN? 
Survival on PN: 






















2.1 Study design 
This master project is part of a multicentre retrospective study which includes all patients with 
incurable cancer receiving intravenous nutrition between 2011 and 2018. The study is a 
collaboration between the Norwegian University of Science and Technology (NTNU) (project 
management), St. Olavs University Hospital (Trondheim), Vestfold Hospital (Tønsberg), 
Hospital in Telemark (Skien) and Haukeland University Hospital (Bergen). The study involves 
several health care levels as patients has discharged from the hospital with intravenous 
nutrition. This is exemplified by homecare services and institutions like long-care facilities or 
short-care facilities. This thesis is based on data collected at Haukeland University Hospital 
during October 2019 and February 2020. 
Haukeland University Hospital and Helse Bergen treat almost 600.000 patients and contribute 
to the education of several thousand health care workers every year [56]. It is the second largest 
university hospital in Norway with regard to research production and employ about 800 persons 
engaged in research activities, which equals 300 full-time positions [57]. 
2.2 Patients 
 Patient recruitment 
This study included patients with incurable cancer starting PN at the hospital and patients 
discharged from the hospital with PN, as well as patients starting PN at palliative care units and 
home, from 1st of January 2011 to 31st of December 2017. Subjects were identified through the 
delivery records of treatment aids, for delivering of infusion pump, provided by Home Care 
Equipment, Department of Clinical Engineering, Helse Bergen.  
 Inclusion criteria  
Inclusion and exclusion criteria are presented in Table 3. Inclusion criteria were adult patients 
diagnosed with advanced/incurable cancer receiving PN treatment during the palliative phase 
of their disease, in the period from 1st of January 2011 to 31st of 2017. Patients had to be 
deceased within the data abstraction period to be included in the analysis. Exclusion criteria 
were patients still alive at the start of data abstraction.  
Table 3. Inclusion and exclusion criteria 
12 
Inclusion criteria  Exclusion criteria 
• Adult patients (aged >18 years) with advanced/incurable cancer • Still alive 
• PN treatment during the palliative phase of the disease  
• Deceased at start of the data abstraction period  
PN=parenteral nutrition 
The records of treatment aids for delivering of infusion pump did not provide any information 
regarding the patient’s diagnosis, which type of infusion treatment that were given nor if the 
patients were still alive or deceased. Identification of subjects complying with the inclusion 
criteria were therefore done in a three-step manner, where step 1 included retrieve list of patients 
receiving infusion pump from records of treatment aids, step 2 included checking patients 
records for cancer diagnosis and death, and step 3 checked if the patient did receive PN in a 
palliative phase of his or her cancer diagnosis. 
Step 1: List from records of treatment aids 
Step 2: Checked journal for cancer diagnosis and death 
Step 3: Check if the patient started PN when the disease was incurable 
2.3 Ethics 
The study was approved by the Regional Committee for Medical and Health Research Ethics 
(REC) Mid Norway (Appendix 1) and conducted according to the criteria set by the Declaration 
of Helsinki [58]. The approval from REC gave exemption from gathering consent from 
relatives, due to the patients already being deceased and could not provide written consent. A 
Data Protection Impact Assessment (DPIA) was performed to comply with the requirements of 
General Data Protection Regulations (GDPR) [59]. The DPIA was approved by NTNU and the 
other collaborative institutions. A collaboration agreement between the NTNU and Haukeland 
University Hospital was signed (appendix 2). This study on patients died from cancer poses no 
risk to the patients. Each patient was given an identification (ID) number for de-identification 
in analysis and further use. The ID number were Centre specific and tied to the patient´s name 
and medical record number. The link between ID number and patient name was stored using a 
patient enrolment log which function as a coding key. The coding key were stored in a dedicated 
location with a two-step locking procedure (locked in drawer and locked door in corridor). 
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2.4 Data collection 
Data sources in this study were medical chart records of hospitals, palliative care units and 
primary health care services. Data were collected from the following sections from the patients’ 
medical records; doctor journals, nurse journals, clinical dietitian journals, laboratory tests, 
image diagnostics, nutritional screening, and other registration tools scanned into the electronic 
medical journals. The master student acted as the data abstractor in this study. Data were also 
collected from the following hospitals: Voss Hospital, Haraldsplass Deaconess Hospital (HDS) 
and palliative care unit, Sunniva Centre for Palliative Care at HDS. Data on termination of PN 
were also retrieved from the following primary health care facilities: the home care services in 
the municipality of Bjørnafjorden, Meland nursing home in the municipality of Alver and 
Kleppestø nursing home in the municipality of Askøy. The master student performed requests 
via e-mail and telephone to the primary health care system in order to retrieve information 
regarding PN termination in cases were such data were not reported in the hospital journals. 
 Variables 
Data collected is summarized in Table 4. From medical journal systems, data on demographics, 
comorbidities [60], cancer disease [5] and treatment, date of death, symptom registrations 
(Edmonton Symptom Assessment System, [61]), physical function (ECOG performance status 
scale [34]), biochemical data as well as registrations on nutritional status, food intake and PN 
treatment was retrieved. Data on estimated energy requirements were collected from the 
patient’s journal. Method for estimating energy requirements was not registered. A pause in PN 
treatment was defined as a break of 1-14 days. A break lasting longer than 14 days was regarded 
as start of new PN treatment. If a patient had received PN treatment several times during his or 
her disease trajectory, data on the last PN treatment was registered. The duration of PN 
treatment was calculated from date of start of PN and date of PN termination. Survival from 
PN start was calculated from date of PN start and date of patient death. Survival from PN 
termination was calculated from date of PN termination and date of patient death. BMI (weight 
in kilograms/height in meters squared (kg/m2) was calculated from height and weight 
registrations at PN start. Weight loss in kilograms (kg) at PN start were calculated from 
available body weight taken 4-6 months, 2-3 months and 2 weeks-1 months before PN start. 
Per cent weight loss at start of PN was calculated based on weight loss data. The mGPS was 
calculated from available CRP and albumin values, where CRP >10 mg/L and albumin <35 g/L 
provided a score of 2, a CRP level >10 mg/L provided a score of 1 and CRP ≤10 mg/L and 
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albumin ≥35 g/L provided a score of 0 [24]. Estimated energy needs in kcal/kg/day was 
calculated from data on estimated energy needs and weight registrations at start of PN. Start 
dose of PN in kcal/kg/day was calculated from PN start dose and weight registration at PN start. 
Maximum PN dose received in kcal/kg/day was calculated from maximum dose received and 
weight registration at PN start. 
Table 4. Data collection 
Assessment At PN start  During PN  
Demographics (year of birth, sex, main provision of care) x  
Comorbidities x  
Current medications x  
Cancer type and stage (date of diagnosis and cancer stage at initiation 
of PN) 
x x 
Oncology treatment (previous, ongoing and new treatment during PN) x x 
Estimated energy requirements x  
Food intake registrations x x 
Parenteral nutrition (indication, infusion schedule, dose given, delivery 
rate, dose adjustments, pause in treatment, reason for termination) 
 x 
Nutritional status (height, body weight, previous weight (4-6 months, 
3-4 months and 14 days-1month before PN start, NRS2002) 
x x 
Performance status (ECOG/WHO) x x 
CT scan for body composition measures x x 
ESAS symptom scale (fatigue, nausea, vomiting, shortness of breath, 
appetite, depression, anxiety, wellbeing) 
x x 
Adverse events (oedema, ascites, dyspnoea, nausea, vomiting, 
diarrhoea, feeling cold, feeling warm, dizziness, headache, infections, 
thrombophlebitis, elevated levels of liver enzymes, sepsis, tachycardia, 
hypotension, hypertension) 
 x 
Biological parameters (CRP, albumin, electrolytes) x x 
Date of death  x 
Calculated variables   
Duration of PN  
Survival from PN  
BMI, % weight loss  
mGPS  
Estimated energy needs in kcal/kg/day 
PN start dose in kcal/kg/day 
PN maximum dose in kcal/kg/day 
BMI=Body mass index; CRP=C-reactive protein; ECOG=Eastern European Cooperative Oncology group; 
ESAS=Edmonton Symptom Assessment System; kcal=kilocalories; kg=kilograms; mGPS=modified Glasgow 




2.5 Data abstraction software 
The data collection was performed by a web-based data collection system (WebCRF3) 
developed and administered by Unit of Applied Clinical Research, The Faculty of Medicine 
and Health Sciences, NTNU, Trondheim, Norway. A two-factor authentication was needed to 
access the Web-CRF as an extra level of security. This included a study user with password and 
a URC code sent to the user by SMS. The Web-CRF in this study is the 3.0 version. Data from 
the medical charts were directly entered to the Web-CRF electronically, by the data abstractor. 
 Research manual  
A research manual for data abstraction has been developed to ensure standardizing and 
consistency of data collected from medical journals at several study sites by different 
abstractors (appendix 3). The research manual defined different variables related to the web-
CRF and included information on the inclusion/-exclusion criteria, staging of cancer disease 
and comorbidity [60] as well as definition and response options on other parameters such as: 
performance status [34], nutritional status [62], symptoms [61], indication for PN start, PN 
infusion, and definition of pauses of PN treatment. The research manual was continuous subject 
to changes when challenging variables had to be described in further detail or clarified.  
 Data monitoring  
An overview of variables monitored is presented in Table 5. The data abstractor was introduced 
to the Web-CRF by the research team at NTNU prior to data collection. Data abstractor and the 
research team were frequently in contact with each other during the data abstraction period. 
When uncertainty regarding documentation arose, this was solved by discussion. Monitoring 
of data was performed by the research team in Trondheim post data abstraction. Starting dose 
in all patients registered with a start dose of ≥1600 kcal/day was controlled by the monitor. 
Monitoring of the rest of the variables was done by randomly checking 10% of the included 
CRFs towards the original medical records. Randomization of the 133 included CRFs was 
performed in Microsoft® Excel (version 16.35), by using the formula: 
=RANDBETWEEN(A1;A133), which generated 13 numbers from the sample. When error was 
detected, this was consecutively corrected by abstractor with monitor present. Sources of data 
verification by monitoring included variables on eligibility criteria, PN treatment and cancer 
stage (Table 5).  
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Table 5. Overview of variables monitored 
 
PN=parenteral nutrition, kcal=kilocalories 
2.6 Data processing and analyses 
The data abstraction and processing are presented in figure 2. The datafiles extracted from the 
Web-CRF were stored using a dedicated solution for secure processing of sensitive personal 
data in research, SAFE, provided by UiB. Access to the SAFE-desktop for this project 
demanded a two-factor authentication. In addition to a username and password, the user needed 
to supply a one-time code received as a text message. All processing of data and analyses were 
conducted using this safe desktop.  
 
Figure 2. Process of data abstraction and processing.  
Statistical analyses were performed by using the statistical program IBM SPSS (version 
25.0.0.2). Graphs were made in Microsoft® Excel (version 16.35). Demographics such as age, 
weight, gender, height, BMI and weight loss were reported as means with standard deviation 
(SD). Normality was assessed by normality tests, histograms, normal and detrended Q-Q plots. 
Continuous variables were reported as mean with (SD) values or median with minimum and 
maximum (min-max) or inter quartile range (IQR) with upper and lower quartiles (Q1-Q3) 
Data from patient 
medical records
Web-CRF SPSS datafiles stored 
in SAFE
Analyses and 
processing of datafiles 
in SPSS
Graphs made in Excel
Sample monitored Source of data verification 
The entire population PN start dose ≥1600kcal/day 
 Were PN start dose of 1600 kcal/ day or more correctly registered? 
10 % of the population Eligibility criteria 
 Was patient dead by end of data abstraction? 
 Did patient receive PN between 1st of January 2011 and 31st December 2017? 
 Was patient diagnosed with advanced/ incurable cancer? 
PN treatment 
 Was date of PN start correctly registered? 
 Was date of PN termination correctly registered? 
 Was Indication for PN start correctly registered? 
Cancer disease 
 Was list of medication correctly registered? 
 Was disease stage at PN start correctly registered? 
Was disease stage during PN treatment correctly registered? 
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based on normality. A Wilcoxon signed-rank test was conducted to determine any difference 
in median values of PN max dose and estimated energy needs in kcal/kg/day. A Spearman´s 
rank-order correlation with scatterplot was run to assess the relationship between survival from 
PN start and duration of PN. Kruskal Wallis Test for independent selections was used to 
compare multiple non-parametric variables. Post Hoc Test with pairwise comparisons by 
Dunn´s Procedure with a Bonferroni correction for multiple comparations was used to locate 
any difference between groups in multiple group analysis. Missing data were handled by 
excluding cases in SPSS. Statistical significance level was set at p<0.05 (2-sided) level. 
2.7 Contribution by the master student  
The master student was responsible for all data abstraction at Haukeland University hospital. 
In patients discharged from the hospital to a palliative care unit, long-term facility or home with 
PN treatment, the student was responsible to contact these to request information regarding data 
not reported in the hospital journals. This included communication with the primary health care 

















 Patient identification 
The three-step sample selection process is illustrated in figure 3. From the delivery records of 
infusion pumps provided by Home Care Equipment, Department of Clinical Engineering, Helse 
Bergen, 263 patients receiving infusion pump in the period 2011-2018 were identified. Five of 
these patients were not found in the journal record system of the hospital. Out of 258 patients 
examined for eligibility, 125 (48.4 %) were excluded due to still being alive (n=79), being a 
child (n=1), no received PN treatment (n=14), no cancer diagnosis (n=16), having a curable 
cancer disease (n=10), patients starting PN before 2011 or after 2017 (n=3) and uncertainties 
regarding last PN treatment, meaning that we could not for sure say if the PN treatment was the 
patient´s last, due to patient moving to another region and might receive PN at another health 
region (n=2). In total 133 (51.6%) out of the 258 eligible patients were included in the master 
thesis.  
 
Figure 3. Sample selection flow chart. PN=parenteral nutrition, n indicates number of cases.  
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 Patient characteristics  
Patient characteristics are summarized in Table 6. Mean (SD) age of the population was 64 
(12,4) years and 61 (45.9%) were male. Hospital/palliative care unit was the main provision 
of care for most of the patients included in this study (n=98, 73.7%). The most common types 
of cancer were upper GI (n=48, 36.1%) and colorectal (n=31, 23.3%). Cancers listed under 
“other” were cancers of unknown primary site, peritoneum, prostate, bone, head and neck, 
lymphoma and connective tissue of pelvis, appeared in 16 (12.0%). At start of PN, 111 (83.5%) 
of the patients were diagnosed with metastatic cancer. Metastases in peritoneum-mesentery was 
the most common sites of metastasis and reported in 46 (34.6%) of the cases. Metastasis in the 
liver were present in 41 (30.8%), in lymph nodes 39 (29.3%) and peritoneal carcinomatosis in 
38 (28.6%). Performance status assessed by ECOG/WHO performance status scale was only 
documented in 61 (45.9%) of the patients at start of PN. Performance status ≤2 was most 
frequent (n=40, 30.1%). Twenty-one (15.5%) of the patients were registered with a 



















Table 6. Patient characteristics 
Characteristics Patients, n (%) 
(n=133) 
Mean (SD) 
Age in years  64 (±12,4) 
Gender   
 Female 72 (54.1%)  
 Male 61 (45.9%)  
Main provision of care   
 Hospital/ Palliative care unit 98 (73.7%)  
 Home 34 (25.6%)  
 Long-term care facilities 1 (0.8)  
Cancer diagnosis   
 Upper GI tract 48 (36.1%)  
 Colorectal 31 (23.3%)  
 Gynaecological 16 (12.0%)  
 Small intestine 9 (6.8%)  
 Bladder  6 (4.5%)  
 Lung 4 (3.0%)  
 Breast 3 (2.3%)  
 Other 16 (12.0%)  
Stage of cancer disease   
 Local 10 (7.5%)  
 Locally advanced 12 (9.0%)  
 Metastatic 111 (83.5%)  
Location of metastasis   
 Peritoneum-mesentery 46 (34.6%)  
 Liver 41 (30.8%)  
 Lymph nodes 39 (29.3%)  
 Peritoneal carcinomatosis 38 (28.6%)  
 Lung 19 (14.3%)  
 Bone 13 (9.8%)  
 Other 28 (21.1%)  
Performance status   
 ECOG 1 10 (7.5%)  
 ECOG 2 30 (22.6%)  
 ECOG 3 21 (15.5%)  
 ECOG 4 0  
 No ECOG registered 72 (54.1%)  
ECOG=Eastern European Cooperative Oncology group; mGPS=modified Glasgow Prognostic score; 






An overview of ongoing anti-cancer treatment and use of medications and at PN start is 
presented in Table 7. Most of the patients (n=115, 86.5%) had at some point received different 
anti-cancer treatments for their cancer disease (data not shown). Fifty-two (39.1%) out of 133 
patients received anti-cancer treatment at start of PN, whereof ongoing chemotherapy was the 
most frequent (n=36, 27.1%). Current medications included medication of regular use as well 
as medication prescribed and used when necessary at start of PN. The medications were 
registered in selected drug groups (Table 7). The most frequent medications in this population 
were antiemetics (n=102, 76.7%), non-opioid analgesics (n=98, 73.7%) and opioids 
(n=92, 69.2%). Other medications included among other things thyroid hormones, oestrogens, 
mucolytics and lipid-lowering drugs. 
Table 7. Current medications, ongoing and previous anti-cancer treatment 
Anti-cancer treatment and medication n (%) 
Ongoing anti-cancer treatment  
 None 81(60.9%) 
 Chemotherapy 36 (27.1%) 
 Targeted therapy 5 (3.8%) 
 Radiotherapy 5 (3.8%) 
 Chemo-radiotherapy 3 (2.3%) 
 Immunotherapy 3 (2.3%) 
Current medication  
 Antiemetics 102 (76.7%) 
 Opioids 98 (73.7%) 
 Non-opioid analgesics 92 (69.2%) 
 Drug(s) for acid related disorders 81 (60.9%) 
 Laxatives 71 (53.4%) 
 Sedatives/anxiolytics 65 (48.9%) 
 Heart medication/antihypertensives 48 (36.1%) 
 Anticoagulants 45 (33.8%) 
 Antibiotics 35 (26.3%) 
 Corticosteroids 28 (21.1%) 
 Neuroleptics 25 (18.8%) 
 Anticholinergics 18 (13.5%) 
 Antidepressants 17 (12.8%) 
 Diuretics 17 (12.8%) 
 Antimycotics 17 (12.8%) 
 Antidiarrheals 15 (11.3%) 
 NSAIDS 10 (7.5%) 
 Co-analgesics 7 (5.3%) 
 None 1 (0.8%) 
 Other 67 (50.4%) 
NSAIDS=Nonsteroidal anti-inflammatory drugs, n indicates number of cases.  
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Data on anthropometric measures and biological parameters on inflammation are presented in 
Table 8. Bodyweight at start of PN was available in 126 (91.0%) patients. Mean (SD) BMI was 
21,2 (4,0) kg/m2. Weight loss within the past four to six months before PN start was available 
for 88 (66.2%) patient. Mean (SD) weight loss within the past four to six months before PN 
start was 11.6 (8,2) %. Nutritional risk screening was performed in 63 (47.4%) patients at PN 
start. Malnutrition diagnosis was registered in 77 (57.9%) of the patients. Most of the patients 
were registered with severe protein-energy malnutrition (n=36, 27.1%). Serum CRP was 
available for 124 (93.2%) patients at PN start. Most of the patients had an elevated CRP level 
at PN start (n=97, 72.9%). Serum albumin was available for 107 (80.5%) patients. 
Hypoalbuminemia was detected in 53 (39.8%) of the patients at start of PN. The mGPS was 















Table 8. Data on anthropometric measures and inflammatory markers.  
Variables Mean (SD) n (%), (n=133) 
Height, cm   
 Female 165 (±5,5) 71 (53.4%)  
 Male 178,4 (±6,4) 61 (45.9%) 
 Missing, n  1 (0.7%) 
Bodyweight, kg 61,9 (±12,5)  
 Female 58,1 (±12,2) 65 (48.9%) 
 Male 66,4 (±11,4) 56 (42.1%) 
 Missing, n   12 (9.0%) 
BMI, kg/m2 21,2 (4,0)  
 <18,5  29 (21.8 %) 
 18,5-24,9  73 54.9%) 
 25-29,9  14 (10.5%) 
 >30  5 (3.8%) 
 Missing, n  12 (9.0%) 
Weight loss before PN start, %   
 4-6 months before PN start  11,6 (8,2) 88 (66.2%) 
 Missing, n  45 (33.8%) 
 2-3 months before PN start  8,1 (8,2) 91 (68.4%) 
 Missing, n  42 (31.4%) 
 2 weeks-1 months before PN start  2,5 (6,6) 95 (71.4%) 
 Missing, n  38 (28.6%) 
NRS2002  63 (47.4%) 
 Not at nutritional risk (score< 3)   9 (6.8%) 
 At nutritional risk (score≥ 3)   50 (37.6%) 
 Missing, n   4 (3.0%) 
Malnutrition diagnosis (ICD-10)  77 (57.9%) 
 Severe protein-energy malnutrition (E43.00)  36 (27.1%) 
 Moderate protein-energy malnutrition (E44.00)  15 (11.3%) 
 Unspecified protein-energy malnutrition (E46.00)  26 (19.5%) 
CRP, mg/L    
 CRP≤10  27 (20.3%) 
 CRP>10  97 (72.9%) 
 Missing, n   9 (6.8%) 
Albumin, g/L    
 <35 mg/L  53 (39.8%) 
 ≥35 mg/L  54 (40.6%) 
 Missing, n  26 (19.5%) 
mGPS   
 0   25 (18.8%) 
 1  32 (24.1%) 
 2  44 (33.1%) 
 Missing, n   32 (24.1%) 
BMI=body mass index, cm=centimetre, kg=kilograms, mGPS=modified Glasgow Prognostic Score, NRS2002=nutrition risk 
screening; ICD-10: International classification of diseases version 10, n indicates number of cases. 
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3.2 Parenteral nutrition 
 Indication for start of parenteral nutrition treatment 
Indication for start of PN was available in 132 patients. Indication and number of indications 
for start of PN are presented in Table 9. The most frequent indication for start of PN was 
“insufficient oral and/or enteral intake” reported in 82 (61.7%) of the cases followed by GI 
malfunctions in 52 (39.1%) patients. Several indications were possible, and GI malfunctions 
were often listed together with insufficient oral intake and weight loss and malnutrition were 
often listed together with insufficient oral and/or enteral intake.  
Table 9. Indications for start of PN. 
Indication(s) for start of PN n (%), (n=133) 
 Insufficient oral and/or enteral intake 82 (61.7%) 
 Gastrointestinal malfunctions 52 (39.1%) 
 Weight loss 31 (23.3%) 
 Subileus 21 (15.8%) 
 Patient wish 12 (9.0%) 
 Short bowel syndrome 9 (6.8%) 
 Promote tolerance for cancer treatment 8 (6.2%) 
 Other 41 (30.8%) 
Numbers of indications  
 1 48 (36.1%) 
 2 53 (39.9%) 
 3 24 (10.1%) 
 ≥4 7 (5.3%) 
PN=parenteral nutrition, n indicates number of incidents.  
 Energy requirements and food intake 
Data on estimated energy needs and food intake at PN start is presented in Table 10. Energy 
requirements were estimated in 80 (60.1%) out of 133 patients at PN start. Mean (SD) estimated 
energy requirement was 1781 (228) kcal in women and 2176 (354) kcal in men, equivalent 
to mean (SD) 33 (6) kcal/kg/day. Food registrations were available for 15 (11.3%) patients at 
PN start, ranging from 1-5 days of registration showing a mean intake of 655 kcal/day in women 
and 952 kcal/day in men. Seventy-one (53.4%) of the patients were referred to clinical dietitian 
in relation to start-up and/or follow up of PN treatment. Number of consultations with clinical 
dietitian at start-up/during PN treatment ranged from 1-36, with a median of 2 consultations per 
patient (data not shown). 
 
25 
Table 10. Estimated energy needs and registered intake of food and energy at PN start 
Variables  n (%), (n=133) 
Estimated energy needs, kcal Mean (SD)  
 Female 1781 (228) 42 (31.6%) 
 Male 2176 (354) 38 (28.6%) 
 Total  1969 (354) 80 (60.1%) 
 Missing, n  53 (39.9%) 
Estimated energy needs, kcal/kg Mean (SD)  
 Total 33 () 76 (57.1%) 
 Missing, n  57 (42.9%) 
Registered food intake at PN start, days Median (min-max)  
 Female 1 (1-5) 5 (3.8%) 
 Male 2.5 (1-5) 10 (7.5%) 
 Total  2 (1-5) 15 (11.3%) 
Registered energy intake at PN start, kcal Mean (SD)  
 Female 655 (338) 5 (3.8%) 
 Male 952 (321) 10 (7.5%) 
 Total 853 (346) 15 (11.3%) 
PN=parenteral nutrition; SD=standard deviation; kcal=kilocalories, n indicates number of cases.  
 Administration of parenteral nutrition 
An overview of administration of PN are presented in Table 11. Main route for infusion was 
transthoracic venous port (n=79, 59.4%). Many patients received PN treatment both via 
peripheral vein and central vein at different times of PN treatment. Several options regarding 
route of administration were therefore possible. Nine (6.8%) patients received PN through a 
short-term CVC, while 44 (33.1%) patients received PN through a CVC not further specified. 
Volumat Agilia was the most commonly used infusion pump (n=112, 84.2%). Ambix Active 
was also registered in some patients (n=9, 6.8%), and some patients switched from Volumat 
Agilia to Ambix Active during treatment. Several options were therefore possible. The use of 
no pump was registered in 2 patients. SmofKabiven was the most common PN solution (n=107, 
80.5%) followed by Olimel (n=33, 24.8%). Other PN solutions listed were Kabiven and 
Oliclinomel. Several options were possible since the hospital may change their main distributor 
of solutions each third year. Delivery rate of PN was registered in 79 (59.4%) of the patients 
and starting delivery rate was available for 32 (24.1%) of these patients. Median starting 
delivery rate was 75 ml/hour. The median delivery rate during treatment was 100 (80-120) ml/h 
(data not shown). Most of the patients received infusion at varies time during day or night and 
were therefore listed with “cyclical infusion – other” (n=86, 64.7%). Infusion during night-time 
was registered in 38 (28.6%) of the patients. Most of the patients (n=122, 91.7%) received PN 
7 days a week, although some received PN every other day or less (n=9, 6.8%). 
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Table 11. Administration of PN 
Administration of PN n (%) 
Route for infusion 
 
 Transthoracic venous port 79 (59.4%) 
 Peripheral venous catheter 68 (51.1%) 
 Central venous catheter  44 (33.1%) 
 Hickman catheter 20 (15.0%) 
 Short term central venous catheter 9 (6.8%) 
Type of infusion pump 
 
 Volumat Agilia 112 (84.2%) 
 Unknown 13 (9.8%) 
 Ambix Active 9 (6.8%) 
 No pump 2 (1.5%) 
PN solution 
 
 SMOFkabiven 107 (80.5%) 
 Olimel 33 (24.8%) 
 Other 4 (3.0%) 
Infusion type  
 Cyclical infusion – other 86 (64.7%) 
 Cyclical infusion – nightly 
infusion 
38 (28.6%) 
 Missing 9 (6.8%) 
PN treatment days a week  
 7 days 122 (91.7%) 
 4 days 6 (4.5%) 
 3 days 3 (2.3%) 
 1, 2, 5 or 6 days 0 
 Missing 2 (1.5%) 
PN=parenteral nutrition, n indicates number of cases 
 Dosage of parenteral nutrition 
Details on PN treatment and dosages are presented in Table 12. Starting dose of PN was 
available in 132 patients (99.3%). Median start dose (Q1-Q3) was 1000 (570-1100) kcal. The 
population was divided into 4 subgroups based on the amount of energy provided by the PN 
start dose: ≤500 kcal, >500 kcal-≤1000 kcal, >500 kcal-≤1000 kcal and >1500 kcal. Most of 
the patients was allocated to the group with a PN start dose >500 kcal-≤1000 kcal 




Table 12. PN start dose 
Variables Kcal/day, median (Q1-Q3) n (%), (n=133) 
PN start dose 1000 (570-1100) 132 (99.3%) 
Subgroups based on PN start dose   
 ≤500 kcal 446 (245-500) 11 (8.3%) 
 >500 kcal-≤1000 kcal 1000 (550-1000) 70 (52.6%) 
 >1000 kcal-≤1500 kcal 1100 (1050-1100) 40 (30.1%) 
 >1500 kcal 1600 (1600-1710) 11 (8.3%) 
 Missing  1 (0.7%) 
PN=parenteral nutrition; kcal=kilocalories. N indicates number of cases.  
A comparison of median PN start dose, maximum dose received, and minimum dose received 
during PN treatment in subgroups defined by PN start dose is presented in figure 4. Twenty-
seven (20.3%) of the patients did not have any dose adjustment from PN start dose. Median 
(Q1-Q3) start dose for these patients was 1100 (1000-1600) kcal (data not shown).  
 
Figure 4. Histogram of median PN start, maximum and minimum dose in subgroups defined by PN start dose. 
Error bars indicates IQR expressed as range (Q1-Q3). Kcal=kilocalories, n indicates number of cases. 
A histogram comparing PN start dose, maximum PN dose received and estimated energy needs 
in kcal/kg/day are presented in figure 5. Median (Q1-Q3) estimated energy needs was 33 (28-
36) kcal/kg/day. Median (Q1-Q3) highest dose PN received was 28 (23-31) kcal/kg/day, which 
is 5 kcal/kg/day lower than median estimated energy needs, p<0.001 assessed by Wilcoxon 
Signed Rank Test. Median (Q1-Q3) per cent of the energy needs this dose covered was 88 (71-





















Start dose Maximum dose received Minimum dose received
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Figure 5. Histogram of median PN start dose and maximum dose of PN received compared to estimated energy 
needs. Error bars in indicates IQR expressed as range (Q1-Q3). Kcal=kilocalories; kg=kilograms; PN=parenteral 
nutrition, n=76.  
 Duration of parenteral nutrition 
Date of PN termination was available in 111 (83.5%) out of 133 patients. Duration of PN 
treatment in all patients and subgroups based on the duration of PN are presented in table 13. 
Median (Q1-Q3) duration of PN was 44 (18-99) days. About 50% of the patients received PN 
≤2 months.  
Table 13. Duration of PN in days 
 Days, median (Q1-Q3) n (%) (n=133) 
Duration of PN 44 (18-99) 111 (83.5%) 
 Missing  22 (16.5%) 
Subgroups based on PN duration   
 ≤2weeks 6 (2-12) 24 (18.1%) 
 >2weeks-≤1month 21 (19-22) 22 (16.5%) 
 >1month-≤2months 43 (29-47) 17 (12.8%) 
 >2months-≤3months  67 (64-75) 18 (13.5%) 
 >3months 139 (107-290) 30 (22.6%) 
 Missing, n  22 (16.5%) 
PN=parenteral nutrition;Q=quartile. N indicates number of cases.  
Table 14 shows a comparison of mGPS at start of PN, pauses during PN treatment and survival 
from PN start and PN termination in subgroups defined by PN duration. There was a difference 
in mGPS at start of PN (p=0.04) assessed by Kruskal Wallis Test for independent selections. 
The mGPS at PN start was higher in the group receiving PN >2weeks-≤1 month compared to 
patients receiving PN ≤2weeks when pairwise compared with Dunn´s Post Hoc Test with a 
Bonferroni correction for multiple comparations. (p=0.04). A Spearman´s rank-order 























PN. There was a positive correlation between duration of PN and survival from PN start, 
correlation coefficient rs=0.751, p<0.0005 (scatterplot not shown). Survival from PN start was 
higher in patients receiving PN >3 months compared to patients receiving PN ≤14 days 
(p<0.001), >1month-≤2 months (p<0.001) and >2 months- ≤3 months (p=0.005) when pairwise 
compared with Dunn´s Post Hoc Test with a Bonferroni correction for multiple comparations.  
Table 14. The mGPS at PN start, pauses during PN and survival from PN start and termination in 


















PN start      
 mGPS, n (%)      
  0 6 (25.0%) 2 (9.1%) 2 (11.8%) 2 (11.1%) 6 (20.0%) 
  1 7 (29.2%) 2 (9.1%) 3 (17.6%) 6 (33.3%) 9 (30.0%) 
  2 3 (12.5%) 11 (50.0%) 7 (41.2%) 8 (44.4%) 8 (26.7%) 
  Missing, n (%) 8 (33.3 %) 7 (31.8%) 5 (29.4%) 2 (11.1%) 7 (23.3%) 
During PN      
 Pauses      
  Yes, n (%) 12 (50%) 2 (9.1%) 9 (52.9%) 11 (61.1%) 21 (70%) 
 Unknown, n (%) 1 (4.2%) 3 (13.6%) 5 (29.4%) 3 (16.7%) 5 (16.7) 
Number of pauses, 
median (Q1-Q3) 
1 (1-2) 2 (1-2) 2 (1-3) 1 (1-2) 2 (1-3) 
Survival      
 Survival from PN start, 
days, median (Q1-Q3) 
37 (17-137) * 47 (26-164) * 58 (43-95) * 77 (68-96) ** 167 (131-
322) *,** 
 Survival from PN 
termination, days, 
median (Q1-Q3) 
33 (6-129) 26 (3-144) 8 (5-52) 6 (2-24) 9 (5-43) 
PN=PN; mGPS=modified Glasgow Prognostic Score; SD=standard deviation; Q=Quartile. Kruskal Wallis Test 
for independent selections, Post Hoc Test, Pairwise comparisons by Dunn´s Procedure with a Bonferroni 
correction for multiple comparations; *p<0,001, **p=0,005. N indicates number of cases.  
 Reasons for discontinuation of parenteral nutrition 
Reason for discontinuation of PN was registered for 112 (84.2%) patients and are presented in 
Table 15. Several options were possible. Most of the patients had a singular reason for PN 
termination (n=78, 58.6%). The most common reason for PN termination was “patient is 
terminal/has short/very short expected survival” (n=50, 37.6%). Reasons listed under “other” 
included: “patient does not wish to receive life-prolonging treatment”, “patient does no longer 
benefit from PN”, “rapidly progressive disease/disease progression”, “patient wish”, “patient 




Table 15. Reason(s) for discontinuation of PN treatment 
Reason for discontinuation of PN treatment n (%) 
 Patient is terminal/short/very short expected survival 50 (37.6%) 
 Complications related to PN treatment 16 (12.0%) 
 Transition to oral food intake 10 (7.5%) 
 Recovery of GI tract functions 9 (6.8%) 
 Transition to enteral nutrition treatment 8 (6.0%) 
 Unknown 7 (5.3%) 
 Patient wish due to burden of PN treatment 6 (4.5%) 
 Patient wish to resume oral food intake 4 (3%) 
 Other 27 (20.3%) 
Number of reasons  
 1 78 (58.6%) 
 2 33 (24.6%) 
 3 1 (0.8%) 
GI=gastrointestinal, PN=parenteral nutrition, n indicates number of cases. 
 Survival 
Data on survival were available for all of the patients. Details are presented in Table 16. Median 
(Q1-Q3)) survival for the population was 81 (41-159 days). Half of the patients survived ≤3 
months (n=71, 53.4%).  
Table 16 Survival from PN start. 
 Survival in days, median (Q1-Q3) n (%), (n=133) 
Survival from PN start  81 (41-159) 133 (100%) 
Subgoups based on survival from PN start   
 ≤1 month 19 (14-22) 19 (14.3%) 
 >1 month- ≤ 2 months 41 (33-47) 28 (21.1%) 
 >2 months- ≤ 3 months 69 (66-80) 24 (18.0%) 
 >3 months- ≤ 6 months 119 (104-152) 34 (25.6%) 
 >6 months 303 (226-428) 28 (21.1%) 
PN=parenteral nutrition, n indicates number of cases.  
The mGPS at PN start and indications for PN start in subgroups defined by survival from PN 
start is presented in Table 17. There was no difference in the distribution of mGPS at PN start 
between the subgroups (p=0.7), assessed by Kruskal Wallis test for independent selections. 
Insufficient oral and/or enteral intake followed by GI malfunctions/subileus was the most 
frequent indications for start of PN across the subgroups (table 17).  
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Table 17. The mGPS at PN start and indication(s) for start of PN in subgroups defined by survival. 






≤ 3 months 
(n=24) 
>3 months- 




mGPS, n (%)      
 0 3 (15.8%) 5 (17.9%) 5 (20.8%) 6 (17.6%) 6 (21.4%) 
 1 3 (15.8%) 3 (10.7%) 9 (37.5%) 10 (29.4%) 7 (25.0%) 
 2 5 (26.3%) 13 (46.4%) 7 (29.22%) 11 (32.4%) 8 (28.6%) 
 
Missing 8 (42.1%) 7 (25%) 3 (12.5%) 7 (20.6%) 7 (25.0%) 
Indication for start of PN, n (%)      
 Insufficient oral and/or enteral intake 13 (68.4%) 17 (60.7%) 16 (66.7%) 20 (58.8%) 16 (57.1%) 
 GI malfunctions/subileus 9 (47.3%) 14 (50.0%) 16 (66.7%) 20 (58.8%) 14 (50.0%) 
 Weight loss 3 (15.8%) 5 (17.9%) 7 (29.2%) 9 (26.5%) 7 (25.0%) 
 Patient wish 3 (15.8%) 5 (17.9%) 2 (8.3%) 2 (5.9%) 0 
 Short bowel syndrome 0 2 (7.1%) 0 0 7 (25.0%) 
 Promote tolerance for anti-cancer treatment 0 0 1 (4.2%) 4 (11.8%) 3 (10.7%) 
 Other 8 (42.1%) 7 (25.0%) 10 (41.7%) 12 (35.3%) 10 (35.7%) 





















The PATNIC-study is to our knowledge the first study examining current practice of PN 
therapy in patients with incurable cancer in Norway. The study is a multi-centre study and 
includes two university hospitals and two local hospitals. PN therapy in patients with incurable 
cancer is subject to debate due to conflicting evidence regarding its risks and benefits. We know 
little about how PN is administered in this patient group in terms of dosages, duration and 
survival. This study aimed to describe the current practice of PN therapy in patients with 
incurable cancer at Haukeland University Hospital in the period 1st of January 2011 to 31st of 
December 2017. First, the main findings of the study will be presented, followed by discussion 
of method and results.  
 Main findings 
In total, 133 patients were included. Cancers in the upper GI tract and colorectal cancer were 
the most common types of cancer and the majority of the population had metastases at PN start. 
The majority of the patients had suffered from weight loss demonstrating severe malnutrition 
at PN start. The most common reported indication for PN start was insufficient oral and/or 
enteral intake followed by GI malfunctions/subileus. Food registrations were conducted in 15 
(11.3%) patients at PN start and showed a low intake in all patients, supporting indication of 
nutritional treatment according to guidelines. Mean (SD) estimated energy requirements was 
33 (6) kcal/kg/day. Data on dosages of PN indicates that most of the patients starts on a low 
dose and that the maximum dose ever received is lower than estimated energy requirements. 
Some does also have one or more pauses during treatment, resulting in a lower overall dose of 
PN received. About one-half of the patients receive PN ≤ 2 months and 53.4 % of the population 
survives ≤3 months. Most of the patients receive PN therapy a few weeks or days from death. 
Discontinuation of PN was based on expected survival, complications related to treatment and 
patient wishes related to treatment.  
4.2 Discussion of methods 
This study is a retrospective medical chart review, where pre-recorded data from patient 
journals at Haukeland University hospital were collected. Some limitations regarding the study 
design and methods as well as advantages will be discussed in further detail.  
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 Limitations 
4.2.1.1 Incomplete/missing data 
The data used in this study were not originally recorded in order to answer the research 
questions set prior to the study. This implies that the level of documentation and quality of the 
data is uncertain when using retrospective study design. Some records may be incomplete or 
lost with time, which may result in missing data in some variables [63, 64]. Initially, we wanted 
to investigate treatment plans, goals and evaluation of PN among other things, but due to lack 
of documentation practice and systematic reporting, this was not possible. We also experienced 
that some variables had more missing data than other variables, e.g., data on food intake at start 
of PN, ESAS symptom scale, performance status and infusion rates of PN. Lacking data on 
some of the variables in a patient journal can lead to nonresponse bias, which implies that 
subjects with missing data may differ systematically from the others [63]. Cases with missing 
variables were handled by excluding them from the analysis, resulting in a reduced sample size. 
In our experience, documentation practices on PN treatment vary among health care 
professionals. Data on PN treatment were available in various amounts in almost all patients in 
this study, making it possible to describe PN treatment in terms of dosages and duration for this 
population. However, reporting of PN in terms of doses were not done systematically, and doses 
were registered both in volume of the prescribed PN dose in millilitres and kcal/day. 
Nevertheless, in cases where patients were in and out of the hospital and experienced dose 
adjustments, reduced amounts of PN given due to complications or pauses in treatment, increase 
the chance of lacking data on PN treatment for some patients. Also, data on PN termination 
were in some cases non-retrievable in the journal system of the primary health care 
municipalities due to an updated journal system. The most ideally for data collection of this 
study would have been a system where information at different health care levels and from 
different health care providers were available in one platform, making it possible to look at PN 
treatment at all levels in the health care system. 
4.2.1.2 Quality and sources of information 
Difficulty in interpreting or verifying documented information and variability in the quality of 
documentation practices among health care personnel may pose a challenge in retrospective 
chart reviews [63, 65]. There may also exist a spectrum of data quality in patients’ medical 
journal, depending on different documentation practices [63]. Variables in this study were 
collected from journals based on free-text format as well as scanned documents into the patient 
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journals (e.g., patient curve which included data on weight registrations, PN treatment and 
medications, food registrations). In some cases, we experienced difficulty in interpreting 
documented information (e.g, interpret handwriting) in the patient journals. The hospital has 
also been through a transition from medical curves in paper-format to electronical curves. We 
experienced that it was a lot more efficient to collect information from the patient journals on 
variables such as medication, PN treatment, actually dose given and type of solution as well as 
weight registrations, in patients where the use of electronical curves had been implemented. 
The electronical curves may also give more reliable information, due to the prescriptions are 
being directly entered to the data programme, which reduces the risk for abstraction bias (e.g., 
when interpreting handwriting or converting ml of doses to kcal). The chance of different 
quality of information gathered in this study is present due to the use of different systems of 
reporting in the medical records.  
4.2.1.3 Training of data abstractor 
Interpreting data in patient´s medical journal and how to enter and code data is challenging and 
requires training [66]. Training of the data abstractor in terms of how to use and enter data in 
the Web-CRF was performed prior to data collection. Briefing in the electronic chart system 
was not done, due to different chart systems at the different study centres. However, the research 
manual included detailed information on which documents in the patient's journal different 
variables could be found. The data abstractor was also frequently in contact with the research 
team when challenges in reporting different variables arose, which is in line with 
recommendations for conducting a retrospective medical chart review [64].  
4.2.1.4 Data abstraction 
In this study, we used a web-based case report form and collected data were directly entered 
the Web-CRF. Direct registration of data into the database reduces “the number of omitted, 
illegible or mistranscribed entries”, which can occur when using paper-based response 
forms [63]. It is recommended that data abstractors of medical record studies are blinded to the 
research questions of the study to “decrease subjectivity in classification in relation to personal 
theories about the study´s aims” [63]. Data abstraction was performed by the master candidate, 
which means that the data abstractor was not blind to the research questions of the study. This 
may increase the potential for abstraction bias when assigning and interpreting values of certain 
study variables collected from the medical records [63, 66], and constitutes a limitation. The 
abstracter’s accuracy may increase when the abstractors know that their reliability is being 
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monitored [66]. Monitoring of the data abstractor is therefore recommended [66]. This study 
included contact between the research team and data abstractor during the data abstraction 
period. Monitoring was also performed post data abstraction, which may reduce the risk of 
systematic errors and thereby ensure good data control [66].  
4.2.1.5 Plotting errors and data quality control 
The study included many registrations of different variables for each patient and the chance of 
mistakes in plotting values into the Web-CRF, are present. The chance of plotting error may be 
increased in cases where the value had to be manually registered, i.e. plotting of values on 
biological parameters, weight, height, kcal of PN received. We performed a data control in 
SPSS by testing for outliers in the sample on variables such as blood samples and data on PN 
duration. Outliers in the data files from the Web-CRF were double-checked towards the journal 
system and corrected when errors were detected. By doing this, one provides one extra data 
control and enables to correct for possible punching-errors that may occur during data entering, 
thereby reducing the risk of systematic bias. Even though we performed one extra data control 
in SPSS, we cannot exclude the occurrence of other possible punching errors. The chance of 
plotting errors is present using this study design.  
4.2.1.6 Population 
It is recommended to use multiple systems to identify patients, as it may help capture all eligible 
patients for inclusion for the given period, thereby reduce selection bias [66]. However, we did 
in this study only use one system to identify patients receiving PN therapy: by records of 
treatment aids for delivering of infusion pump. There might be a chance that patients receiving 
PN exclusively at the hospital and who were not discharged from the hospital with an infusion 
pump, were missed during the patient enrolment. However, we still believe that we identified 
most of the patients by this method. Other methods (e.g., search for diagnosis/codes for 
diagnoses) probably wouldn’t result in better identification of eligible patients, as one is 
dependent on an infusion pump for PN to be given.  
4.2.1.7 Control group 
Since there is no obvious way to match a heterogenic palliative population or even to identify 
them, historical controls were not used. It would have been difficult, or even impossible, to find 
matching controls with the e.g. same age, gender, diagnosis, anti-cancer treatment, prognosis, 
degree of malnutrition, performance status to properly match the PN group and we did not have 
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any list over potential controls. The design used in this study is descriptive and even if we had 
a control group, we would not be able to conclude on e.g., whether patients survive longer or 
live better with PN or not. 
 Advantages 
An advantage of using this study design is that it is less resource-intensive, in terms of time 
consumption as well as it requires less effort compared to prospective studies [64]. It also 
enables assessment of a large sample at limited cost as well as an easy collection of routinely 
recorded information [64]. If we were to collect all this data prospectively, it would have taken 
the same amount of years, as the timeframe we have collected data from (7 years). The study 
also enables assessment of a large sample at limited cost as well as an easy collection of 
routinely recorded information [64]. Recall bias for events in the past is and the need for 
intrusion into patient´s time for assessment as a part of the study is minimized, and the design 
is not prone to losses to follow-up [64]. In the case of this study, we have the opportunity to 
retrospectively gather information on a treatment in a patient population which is highly 
debated and which we know little about (e.g., how PN is administered and used in this patient’s 
group). Identification of which patients with incurable cancer receiving PN treatment, what 
type of cancer diagnosis they have, indication for start of PN treatment as well as dosages and 
duration of treatment, is valuable information scientists can use when designing studies in 
future research. The results may also contribute to generating hypotheses to be studied further 
in more expensive prospective studies.   
4.3 Discussion of results 
 Indication for start of PN 
The most frequent indication for start of PN was insufficient oral and/or enteral intake reported 
in 82 (61.7%). This differs from findings in the systematic review by Tobberud et al. 
summarizing the effects on PN therapy in patients with advanced cancer, where comprised GI 
function was reported as the main indication for PN in 79% of the patients [12]. Many of the 
patients in our study had lost weight the past 4-6 month before PN start, which indicates that 
they were not able to cover their nutritional needs. The weight loss data may also indicate that 
nutritional deficits were present at PN start in many of the patients, which is also supported by 
reported malnutrition diagnosis in 57% of the patients. In general, the ESPEN guidelines 
recommend EN in patients with insufficient oral intake and intact GI tract [54]. We did not 
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record if patients had gone through other nutritional interventions during their disease trajectory 
prior to PN. However, insufficient oral and/or enteral intake may indicate that either oral intake, 
enteral intake via EN or both are insufficient or not possible. Also, several indications were 
possible and insufficient oral/enteral intake was often listed together with GI malfunctions. GI 
malfunctions, subileus and short bowel syndrome were, in total, listed as indications for PN 
start in 82 (61.7%) of the patients. Patients with GI malfunctions may not be able to cover their 
energy needs by oral intake or even at all. PN therapy is indicated in patients with incurable 
cancer with intestinal obstruction if they are expected to die sooner from starvation than from 
tumour progression [54], and the use of PN seems to be supported by the guidelines in this 
population. One Swedish observational study of the prevalence and use of EN, PN and 
intravenous glucose in cancer patients enrolled in specialized palliative care did report eating 
difficulties and weight loss as the most common indications for PN [67]. Compared to our 
results, this suggests that insufficient oral intake as an indication for PN is commonly used in 
clinical practice.  
Summarizing the indications for start of PN, the findings suggest that the use of PN in patients 
with incurable cancer were in line with the guidelines for PN in patients with cancer. However, 
survival may have an impact on start of PN treatment in these patients and will be further 
discussed under the section on survival on PN.  
 Energy requirement and food intake registrations 
4.3.2.1 Estimated energy requirements  
Energy requirement was estimated at start of PN in 60% of the study population. Method of 
estimation was not recorded, and both rule of thumb (eg., kcal/kg/day) and equations might 
have been used. The mean (SD) estimated energy requirement was 33 (6) kcal/kg/day. This is 
a bit higher compared to the guidelines on nutrition in cancer patient which recommends that 
total energy expenditure should be assumed to be similar to healthy individuals, ranging from 
25-30 kcal/kg/day [22, 54]. Several factors may impact on a patient´s resting energy need 
(REE), including level of systemic inflammation (cachexia), energic demand of the tumour, 
presence of metastases and alterations in body composition [68]. For cancer patients undergoing 
chemotherapy, the variations in REE may be described as a U-shaped curve, independent of 
cancer type and stage [69]. When estimating energy requirements (e.g., by using Harris-
Benedict equation) the risk of over - or underestimating a patient´s energy need (by up to 25%) 
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throughout the treatment period, is present [69]. This constitutes a risk of both under- and 
overfeeding, which in turn may have undesired metabolic effects [22].  
To sum up, the estimation of energy requirements may be difficult due to individual difference 
and may under- or overestimate the energy requirements of a patient. Based on the data, it seems 
estimated energy needs in patients with incurable cancer receiving PN are higher than the 
recommendations [22, 54], which poses a risk for overfeeding, followed by complications, in 
these patients. Future studies should integrate the use of indirect calorimetry, which is the gold 
standard of measurement of basal metabolic rate, to accurately tailor the nutritional treatment 
according to the measured needs of these vulnerable patients with a life-limiting disease [68]. 
4.3.2.2 Oral food intake 
Oral food intake registrations at PN start suggests that patients had an oral intake <60% of their 
estimated energy needs at start of PN (data not shown), which support the use of insufficient 
oral/enteral intake as an indication for PN start. Oral food intake was only documented in 15 
(11.3%) of the patients at PN start, making a generalization about food intake in this study 
difficult. However, reduced food intake is common in patients with cancer [23, 70] and patients 
diagnosed with GI cancers with metastases, may have a reduced oral food intake due to GI-
related symptoms affecting the patient´s ability to eat [71]. GI malfunction was listed as an 
indication for start of PN in many of the patients in this study, which may strengthen the 
assumption of low food intake in the whole population. A patient’s food intake may impact 
what dosages of PN is provided. For future studies on PN therapy, data on food intake prior to 
treatment as well as during treatment should be integrated, to be able to adjust the dosages of 
PN according to oral intake as well as have the opportunity to report on the total energy intake 
in these patients. Several days of food intake registrations might not be appropriate prior to PN 
in patients with weight loss and who have had an insufficient intake over time, and other 
retrospective dietary assessment methods may be used. During treatment, food intake 
registrations may be appropriate.  
 Administration of parenteral nutrition  
4.3.3.1 Administration route and delivery rate 
Most of the patients received PN through the central vein, which is the preferred route for 
infusion of long-term PN. Delivery rates of PN were not routinely recorded in the patient’s 
journal. The median infusion rate during treatment was 100 (80-120) ml/h recorded in 79 
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(59.4%) patients. The median infusion rate equals 1.6 ml/kg/h when divided on the median 
weight of the population, and is in line with the recommendations from Fresenius Kabi, saying 
that the infusion rate should not exceed 2.0 ml/kg/hour for SmofKabiven for central vein, [72]. 
However, a lack of systematic reporting makes it difficult to conclude on these data.  
4.3.3.2 Type of infusion 
Cyclical infusions at varies time during the day or night were most frequent. Normally, one 
may think that PN treatment during night-time is preferred so that the patients do not need to 
be attached to an infusion pump during daytime. PN infusion during daytime may be more 
practical at the hospital but may impact on the patient´s freedom to move and do daily activities, 
due to the physical attachment to the infusion pump during infusion of PN. Patients may also 
experience it as a burden to be dependent on an infusion pump several hours a day. Nightly 
infusion may, therefore, be an option. The disadvantages of PN during night-time may be 
disturbances in sleep due to alarming infusion pump, as well as the need for toilet visits during 
night due to the fluid PN provides. Most of the patients received PN on a daily basis, but some 
patients did receive PN every other day or less. PN every other day or less may be convenient 
for supplemental PN, as it may reduce the total burden of PN treatment due to fewer infusions 
a week with fewer disturbances during night or day. Since the patient is not bound to an infusion 
pump daily, this gives him/her the ability to move more freely. This may, in turn, contribute to 
the maintenance of self-care by reducing these limitations patient´s may experience during PN.  
 Dosages of PN 
4.3.4.1 Start dose 
Median start dose of PN treatment in this population was 1000 kcal/day. Based on the 
subgroups defined by PN start dose, it seems that although some of the patients starts on a lower 
dose, they have a dose adjustment during treatment and the maximum dose received provides 
about the same amount of energy compared to patients starting on a higher dose. For the patients 
with a PN start dose >1500 kcal, we see that they do not increase much from start dose. The 
median lowest dose received in this group was 1000 kcal (figure 4), indicating that this group 
have a reduction in the initial dose. Twenty-seven (20.1%) of the patients did not have any dose 
adjustment from PN start dose. Median start dose for these patients was 1100 kcal. Dose 
adjustments may say something about a patient’s tolerance to PN treatment. Higher doses might 
indicate better tolerance to PN, compared to lower doses. There are no standards for dose and 
volume administration of either PN or simple hydration treatment in palliative care, and such 
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invasive treatments can cause significant complications such as hepatic dysfunction, electrolyte 
abnormalities and volume overload [73, 74]. Current guidelines are based on descriptive studies 
and expert consensuses resulting in vague recommendations such as “applications of PN always 
requires careful weighting of expected individual benefits and risks” [22]. Enhanced evidence 
of PN tolerance is needed to reduce symptom burden and improve personalized nutritional care 
for patients with incurable cancer.  
Patients who have had an insufficient intake over time may be at risk for refeeding syndrome. 
“Refeeding syndrome is defined as the potentially fatal shifts in fluid and electrolytes and may 
occur in severely malnourished patients receiving artificial refeeding” [22]. The National 
Institute for Health and Care Excellence recommends: “PN should be introduced progressively 
and closely monitored, usually starting at no more than 50% of estimated needs for the first 24-
48 hours” [75]. The median PN start dose in this study was 15 kcal/kg/day and made up 
approximately 45% of the median estimated energy requirements (data not shown). This was 
in line with the recommendations.  
4.3.4.2 Energy provided by PN compared to estimated energy requirements 
With respect to energy intake, guidelines recommend providing 25-30 kcal/kg/day [22, 54]. 
The median energy provided by the highest PN dose in this study population was 28 
kcal/kg/day, which was 5 kcal/kg/day lower than their estimated energy needs, but in line with 
the recommendations for nutrition in cancer patients [22, 54]. These data on PN dosages 
indicates that most of the patients receive less than calculated energy needs from PN. For 
patients with one or more pauses in treatment, the overall dose of PN given is lower. Because 
of a lack in the documentation of pauses in this study, it is difficult to establish the accurate 
amount of PN received in patients when including all pauses in treatment. Also, it would have 
been interesting to look at differences between reasons for indications and amount of PN given 
across the groups, as one may think that patients with a GI-malfunction may receive higher 
doses compared to patients able to eat in addition to the PN treatment. One systematic review 
stated that there is a lack of knowledge regarding the optimal PN treatment in patients with 
incurable cancer “as the energy requirement and whether these patients have an anabolic 
potential in response to energy balance is uncertain” [12]. The clinical practice indicates that 
most of the patients with incurable cancer receive less than estimated energy needs from PN 
treatment, they have one or more pauses in treatment, and many have an oral food intake in 
addition to PN treatment.  
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 Duration of parenteral nutrition 
The data suggest that duration of PN treatment in patients with incurable cancer varies from a 
few days to several months, with a median (Q1-Q3) of 44 (18-99) days. The mGPS at PN start 
was higher in the group receiving PN >2weeks-≤1month compared to patients receiving PN ≤2 
weeks (p=0.04). This indicates that mGPS may not have an impact on whether to initiate PN or 
not in this population since mGPS reflects in a way the degree of malnutrition and can change 
upon treatment [76]. The distribution of pauses in treatment varied across the groups and 
indicates that several of the patients have one or more pauses during treatment. Pauses may, as 
previously mentioned, say something about patient’s tolerance to the PN treatment, but may 
also be caused by catheter-related complications, such as blocked catheters, catheter-related 
infections (e.g., locally at the injection site or sepsis) and central vein thrombosis [77]. Not 
surprisingly, there was an association between duration of PN and survival from PN start. 
Patients receiving PN for a longer period also survive longer. Several factors may impact on 
survival in cancer patients such as site and stage of cancer disease, patients response to anti-
cancer treatment, impaired nutritional status and patient age [54]. The data suggest that 
palliative cancer patients are a heterogeneous group with different expected survival from the 
time their cancer cannot be cured.  
 Reasons for discontinuation of parenteral nutrition 
The results suggest that reasons for discontinuation of PN treatment are differentiated among 
patients with incurable cancer and that over one-third of the population receive PN close up to 
death. Patient is terminal or has a short/very short expected survival was reported as a reason 
for discontinuation of PN in 50 (37.6%) of the patients, which indicates that patients receive 
PN treatment close to death. A patient’s condition may change rapidly at this phase of the 
disease trajectory, and it seems that the practice regarding PN therapy is challenging and far 
from easy. Complications of PN treatment were reason for discontinuation of PN treatment in 
16 (12.0 %) of the patients, indicating that some of the patients do experience complications 
during treatment. PN is contraindicated if complications and no perceived benefits from 
treatment occur [54]. Other reasons for discontinuation of PN were patient does no longer 
benefit from PN or rapidly progressive disease. This may indicate that patients have reached a 
terminal stage of their disease and will not have any benefit from the treatment. In this phase 
of the disease, the treatment focus is symptom relief, and according to the guidelines, PN or 
fluid treatment is not recommended [22, 78]. Patients with incurable cancer will sooner or later 
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die from their disease, and medical nutrition therapy, such as PN, cannot change this. It is 
therefore essential to improve the knowledge of when PN is contraindicated and when to 
terminate treatment where the burden outweighs the benefits. 
 Survival  
The data suggest that survival in patients with incurable cancer receiving PN is heterogeneous 
and quite varied ranging from a few weeks to several years, and that PN is used in patients with 
a short survival (1 to 2 months). This is an interesting observation, as PN usually is not indicated 
if expected survival is less than 1-3 months [22, 78]. This suggests that initiation of PN may 
not only be based on available evidence [22] alone but that also ethical aspects such as possible 
physiologic and/or psychological benefits may have an impact on the clinical decision. Active 
feeding is regarded as essential in some cultures [22]. According to guidelines on ethical aspects 
of artificial nutrition and hydration, “there are no clear criteria to ascertain the beginning of the 
dying phase. Therefore, a nutritional intervention in this phase of life should be followed in an 
individualized manner” [79]. PN may be administered in patients with short survival and 
withdrawn if no benefits are achieved or complications occur [79]. In cases were GI 
malfunctions are listed as an indication for treatment, the use of PN in patients with a short 
survival may be supported. According to guidelines, the risk of PN is regarded to outweigh its 
benefits for patients with a prognosis of fewer than 2 months [22]. Is there a chance that the 
nutritional intervention is started too late in the disease trajectory? This study design prevents 
us from evaluating this aspect. Does the PN improve survival or does it only serve as a burden 
for the patient? The initiation of PN treatment in patients with short survival and if these patients 
can take advantage of the nutrition provided are questions for debate and more research is 
urgently needed. 
The mGPS was widely distributed across the groups defined by survival from PN start. This is 
an interesting observation since mGPS is related to survival and helps stratify prognosis groups 
[24], suggesting that patients with a short survival from PN start would have a higher mGPS 
compared to patients surviving longer. The data implies that mGPS might not be appropriate as 
a prognostic factor regarding PN treatment as the active nutritional treatment given in this study 
can improve mGPS by increasing albumin levels by amino acid supplementation and reducing 
CRP by e.g., anti-inflammatory omega 3 fatty acids [22, 23], which is given in quite high doses 
in PN, and thereby changing the patients prognosis. To our knowledge, no studies have 
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evaluated the change in this prognostic score by nutritional treatment. This will be evaluated in 
the whole data set if prospective data on CRP and albumin is available in the PATNIC-study.  
5 Conclusion  
The overall aim of this study was to describe the current practice of PN therapy in patients with 
incurable cancer, receiving PN at Haukeland University Hospital, Bergen from 2011-2018.  
The most common reported indication for PN start was insufficient oral and/or enteral intake 
followed by GI malfunctions/subileus. Food registrations was only conducted in 15 patients 
prior to PN treatment and showed a low oral intake in all patients, supporting indication of 
nutritional treatment with PN according to guidelines. Estimations of energy needs in patients 
with incurable cancer receiving PN were higher than the recommendations from the ESPEN 
guidelines on nutrition in cancer patients, and currently used estimates might lead to 
overtreatment in patients if fully nourished. 
Most of the patients received PN on a daily basis, but some patients did receive PN every other 
day or less. PN infusion through central vein was most common and most of the patients 
received PN through cyclical infusions. Median starting dose was approximately 50% lower 
compared to the estimated energy needs and in line with recommendations for initiation of PN. 
The median energy provided by the highest PN dose was lower than estimated energy needs 
and most of the patients received less energy from PN compared to the estimated energy needs. 
For patients with one or more pauses in PN treatment the overall dose of PN given is lower.  
The data suggests that duration of PN treatment in patients with incurable cancer varies from a 
few days to several months. Survival in patients with incurable cancer receiving PN is 
heterogenous and quite varied ranging from a few weeks to years. Patients receiving PN for a 
longer period of time also survive longer. Discontinuation of PN was based on expected 
survival, complications related to treatment as well as tolerance to PN. 
6 Future perspectives 
This study provides data on how PN is administered in patients with incurable cancer in terms 
of dose, duration and termination in clinical practice. Results from this thesis describes how PN 
PN treatment is used in palliative care. Future studies should investigate which patients that 
might have a benefit from PN treatment and who will not. The level of evidence on effects of 
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PN on clinical outcomes such as health-related QoL, physical function, nutritional status, 
survival and adverse events is weak, due to few high quality trials [12].  
Two ongoing RCTs are currently awaited [38, 80], whereof one investigating supplemental PN 
at the palliative phase of advanced cancer [38], and one investigating early supplemental PN in 
metastatic gastric cancer patients at nutritional risk undergoing first-line chemotherapy [80]. In 
both studies, the control group receive nutrition exclusively by the oral route by counseling and 
supplements [38, 80]. In both of the studies, the exact dose of PN ordinated is not described in 
the protocol, as PN is adapted according to residual oral intake [38, 80]. In one of the studies, 
the PN will account for at least 1000 kcal/day and 6 g of nitrogen, on 5 days of 7 [38]. Both 
studies use estimations of energy needs [38, 80], which is related to uncertainties due to 
individual differences in REE, and poses a risk of under- or overestimation a patient’s 
requirements.  
The primary aim of the ALIM-K study is to evaluate the influence of PN on health-related QoL 
deterioration free survival of one of the 3 targeted scores of European Organization for 
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 15 Palliative 
(QLQ-C15-PAL): global health-related QoL, physical functioning and fatigue, and preliminary 
data was presented at American Society of Clinical Oncology conference 2018 [80]. Trends 
towards better QoL, physical function and fatigue as well as less adverse events in favor of 
control arm was reported, and the authors conclude that PN did “not provide clinical benefit for 
advanced cancer patients with numerically reduced overall survival and increased toxicity” 
[81].  
Reported complications and side effects of modern PN treatment have been low, but have 
predominantly been reported as catheter-related infections [12]. Treatment is safer as the 
hygiene protocols have improved and such complications are thus no longer a central concern 
in PN treatment. Many of the patients do already have inserted central catheters for infusion of 
chemotherapy and PN does not involve any extra invasive procedures for these patients. 
However, side-effects such as ascites, oedema and dyspnoea due to high fluid volume 
administration are understudied but often reported as a concern from clinicians working in 
palliative cancer care when patients receive higher doses of PN. This indicates that we not only 
need to know more about effects of PN on survival, physical function and QoL but also 
symptom burden of various doses as well as patients’ actual energy needs in terms of basal 
metabolic rate. 
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The recent Lancet oncology commission on integration of oncology and palliative care states 
that: “To facilitate better patient involvement in cancer care and improved patient-centred 
outcomes, the patient’s voice must be heard by their medical team during shared decision-
making, in terms of symptoms, functions, QoL, and preferences for information provision” [2]. 
To be able to provide the best nutritional care for patients living with incurable cancer, it is 
essential to focus on the patient’s perspective in terms of symptom burden, wishes, nutritional 
needs and doses of PN that are tolerated.  
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FLOW CHART OF STUDY REGISTRATIONS 
Table 1: Study registrations 
Assessment Before 




Demographics (year of birth and sex) x   
Comorbidity  x   
Cancer type and stage (time of diagnosis and cancer 
stage when initiation of PN) 
x  x   
Oncology treatment  x x  
Parenteral nutrition (treatment plan, evaluation 
plan, dose given, delivery rate, dose reduction and 
termination) 
 x  
Current medications x   
Nutrition status (body weight, weight loss, BMI, PG-
SGA, NRS-2002) 
x x  
Physical function (WHO, KPS) x x  
CT scan for body composition measures x x  
ESAS symptom scale 
(fatigue, nausea, vomiting, short of breath, appetite, 
depression, anxiety, wellbeing) 
x x  
Side effects (fluid retention, oedema)  x  
Biological parameters (CRP, albumin, electrolytes) x x  
Benefits of parenteral nutrition  x  










Parenteral Nutrition Therapy in Patients with Incurable Cancer 
This data collection manual was developed as a part of the project: Parenteral nutrition 
therapy in patients with incurable cancer: a retrospective analysis of current practise 
(PATNIC) at the research group for oncology and palliative care, at Norwegian University of 
Science and Technology (NTNU), Trondheim, in 2018. This study is a collaboration between 
NTNU, Trondheim, the Cancer Clinic, St. Olavs University hospital, Trondheim, the 
Department of Oncology, Vestfold Hospital, Tønsberg and the Palliative Care Unit, 
Department of Medicine, Telemark Hospital Trust, Skien. This master thesis is based on data 
from St. Olavs University hospital. A retrospective medical chart review was developed and 
conducted to investigate the following research questions: 
 
 What is the indication for use of parenteral nutrition? 
 What is the treatment goal and plan for evaluation of parenteral nutrition?  
 What is the duration of parenteral nutrition? 
 What are the reasons for discontinuation of parenteral nutrition? 
 What is the dose and method of administration of parenteral nutrition?  
 Are patients receiving parenteral nutrition according to calculated nutritional needs, or 
less than calculated needs? 
 What are the benefits of parenteral nutrition? 
 What is the complications and side effects of parenteral nutrition? 
 How long do patients on parenteral nutrition live? 
 
Further plans for the PATNIC project is to conduct the same retrospective medical chart 
review at Telemark hospital Trust, Skien, Vestfold hospital, Tønsberg and Haukland 








IDENTIFICATION OF PATIENTS 
Identification of patients 
Study coordinator or local investigator is responsible for patient inclusion. Patients are 
identified through patient referral systems at the included hospitals, searchable systems of 
treatment aids record system, as well as searchable system in journal system on diagnosis 
from NCP term for parenteral nutrition treatment.  
 
Patient identification number 
Each patient will be given an ID number for anonymization in analysis and further use. The 
ID number will centre specific and tied to the patient name and medical record number. The 
patient identification number is automatically generated from the Web-CRF and must be 
entered the patient enrolment log. The enrolment log will function as a coding key and will 
be kept locked in a safe location. 
Centre numbers:  
x ST01 St. Olavs Hospital, Trondheim, Norway 
x VE02  Vestfold Hospital, Tønsberg, Norway 
x TE03  Telemark Hospital, Skien, Norway 
x HK04- Haukeland University Hospital, Bergen 
INCLUSION/ EXCLUISION CRITERIA 
All patients must be diagnosed with advanced/ incurable cancer, and given parenteral 
nutrition treatment. Patients must be deceased within the data extraction period to be 
included in analysis.   
 
Advanced, incurable cancer 
Defined as: Not curable cancer, but might respond to cancer treatment or disease-direct 
therapy to prolong life and reduce symptoms.  
 
Use of Parenteral Nutrition 
Use of all parenteral nutrition (PN) therapy include: supplementary PN treatment, peri-
operative PN, PN during oncology treatment, long term PN treatment, total PN treatment 





Data sources included in this study are medical chart records of hospitals and primary health 
care facilities. Data are collected from doctor journals, nurse journals, clinical dietitian 
journals, laboratory tests, image diagnostics, nutritional screening, and other registration 
tools scanned into the electronic medical chart records.  
 
Data abstraction 
Data abstraction requires access to various medical record systems and training of the data 
abstractor in each of the systems. A web-based case response form (CRF) is developed in 
addition to this research manual as a tool for the data abstractor in extraction of data from 
medical records. The data abstractor must be monitored by a data inspector, who will check 
a number for random CRF towards the original medical record to ensure accuracy and inter-
rater reliability of the data abstraction instrument and the data abstractor [1]. This must be 
















Table 2: Where to find relevant information in medical journal and referral systems 
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Journal type Information 
Clinical dietitian referral systems Identification of patients 
Infusion pump register Identification of patients 
Inn-journal Patient characteristics, comorbidities, current 
medication 
Doctor medical journals Information on diagnosis, oncology 
treatment, current medication, 
comorbidities, metastasis, ECOG status, ESAS 
registration, PN treatment, adverse events. 
CT scans.  
Nurse medical journals  Information on patient overall condition, 
food intake, side effects, benefits, clinical 
observations. Check both evaluation and 
summary for thorough documentation.  
Clinical dietitian journals Information on food intake, estimated energy 
needs, nutritional treatment, nutritional 
status, malnutrition diagnosis, information on 
body weight, height and nutritional status. 
Laboratory results Biochemical analysis 
Nutritional screening tools Information on body weight, height, 
nutritional status. 
Patient curve Information on medications, PN treatment, 







Activity registration in journal systems: 
To access a journal, you have to present a reason for access. This might vary between 
different journal systems. Find information on how to access the journal system at your 
study centre. 
E.g. How to access journals for data abstraction in Doculive: 
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 Actualization: Tic  ff  for research  
✓ Fill inn PATNIC E-case number: 1818075 
E g  PATNIC study E-case number 1818075  
Web CRF 
The CRF in this study is web based and developed from a model of the Web-CRF used in the 
MENAC trial developed at PRC Trondheim. Data from the medical chart is entered to the 
Web-CRF electronically, by the data abstractor. The CRF is divided into eight chapters: 1) ID, 
2) Patient characteristics at PN start, 3) PN treatment, 4) Administration of treatment plan, 
5) Adverse events during PN, 6) Patient characteristics during PN treatment, 7) Biochemical 
blood analysis during PN treatment, 8) Death.  
 
Access the Web-CRF system at: https://webcrf3-ur.medisin.ntnu.no/  
Fill in study ID and URC code sent to you by SMS 
1) Register user accounts (in case you do not have one from before) 
2) Register study role (e.g. Study user, only study user can fill in data to Web-CRF) 
3) Register study centre you are affiliated with 
If you already have a username in Web-CRF and need access to a new study, start at 2).  
 
Register patients 
 Log in, choose patient to add new patient or check already included patient 
 Choose the green + sign to add new patient 
  To check registrations on a patient, check the tab behind each patient  
 Whe   ch e e  a ie  g   tudy-parts  for further data registration 
(marked with two sheets over another). 
 Access each part by clicking on the sign marked as a sheet with a pencil 
 Hold cursor over each icon to see what hides behind the icon. 
 
- I f a i   he  ed f c i  ca  be f d i  Q ic  G ide  U e  interface 
a d C  e a i  




Terms of use of CRF 
 Read terms of use of CRF carefully 
 Note that direct copying and pasting of text from electronic health records is not 
allowed. 
 
If you experience any problems with the CRF, describe the issue and send it in an email to 
webcrf@medisin.ntnu.no 
If you experience problems in the data abstraction process, please contact 

















Use of integer and decimals in web CRF 
 Measured body weight (kilograms): 1 decimal (e.g. 60.2) 
 Measured height (centimetre) : 1 decimal (e.g. 171.3) 
 Kilocalories (kcal): 1 decimal (e.g  1580.5) 
 Number of days: only integer (e.g. 9) 
 Sodium: 1 decimal  
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 Potassium: 1 decimal 
 Calcium: 1 decimal 
 Creatinine: only integer (e.g. 48 µmol/L) 
 Phosphate: 1 decimal 
 Magnesium: 1 decimal 
 Hemoglobin (Hb): 1 decimal 
 Leucocytes: 1 decimal (e.g  3.2 109/L) 
 Neutrophils: 1 decimal 
 Lymphocytes: 1 decimal 
 Glucose: 1 decimal 
 CRP: only integer (e.g. 115 mg/L)  
 Albumin: only integer (e.g. 42 g/L) 
 Urea: 1 decimal 
Missing data in web CRF 
Missing data in the web CRF will either be left blank, or egi e ed b  ic i g f  b  f  
missing data or not registered.  
How to fill in the Web-CRF 
o Round boxes: Where the boxes available  ic  ff  a e round shaped there is only 
one available answer. 
□ Squared boxes: Where the b e  a ai ab e  ic  ff  are squared shaped there is 
several available answers. 
- Text fields and comments field is there to fill out what can`t be registered otherwise. 
Try to keep text fields and comment fields short and to the point.  
 
INSTRUCTIONS: DATA ABSTRACTION FROM MEDICAL RECORD TO 
WEB-CRF 
- Study-part 1) and 2) is information before start of PN treatment, find last 
registrations before treatment start, or registrations closest up to treatment start. 
Register information in Web-CRF.  
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- Study-part 3), 4), 5), 6) and 7) is information during last PN treatment patient 
received. Find information registered for this period and register in Web-CRF. 
- Study-part 8) is information regarding termination of treatment and patient death. 
Register information in Web-CRF.  
 
1) Patient identification 
 Fill in year of birth and register patient sex. 
This study part is mandatory and must be filled in order to precede filling out the rest of 
the CRF. When patient is added to the study a unique centre specific ID number will 
automatically be generated. Make sure to note this ID number in the patient enrolment 
log.  
 
2) Patient characteristics at PN start 
 Fill in how patient was identified.  
 Register comorbidities, physical function and current medications as described in 
research manual. 
 Fill in Principle cancer disease and treatment as described at page 17 
 Fill in Nutritional status as described at page 18  
 Fill in CT-scans as described at page 19 
 Fill in ESAS symptom scale as described at page 19  






Insert comorbidity elements identified in the medical journal from to the Web-CRF by 
ic i g f  e e a  di ea e  P ace c bidi ie  i  he  a ia e ca eg ie   
a  ic  f  e e a  b e  if a ie  ha e e e a  c bidi ie  Comorbidities are 
classified using the Charlson comorbidity index (table 3). Do not include comorbidities no 
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Table 3: Instruction for completing the Charlson comorbidity  
Myocardial infarct Hx of medically documented myocardial infarction 
Congestive heart failure Symptomatic CHF w/ response to specific treatment 
Peripheral vascular disease Intermittent claudication, periph. arterial bypass for 
insufficiency, gangrene, acute arterial insufficiency, 
untreated aneurysm (>=6cm) 
Cerebrovascular disease 
(except hemiplegia) 
Hx of TIA, or CVA with no or minor sequelae 
Dementia Chronic cognitive deficit 
Chronic pulmonary disease Symptomatic dyspnea due to chronic respiratory 
conditions (including asthma) 
Connective tissue disease SLE, polymyositis, mixed CTD, polymyalgia 
rheumatica, moderate to severe RA 
Ulcer disease Patients who have required treatment for Pepticulcer 
disease 
Mild liver disease Cirrhosis without Portal hypertension, chronic hepatitis 
Diabetes (without 
complications) 
Diabetes with medication 
Diabetes with end organ 
damage 
Retinopathy, neuropathy, nephropathy 
Hemiplegia (or paraplegia) Hemiplegia or paraplegia 
Moderate or severe renal 
disease 
Creatinine >3mg% (265 umol/l), dialysis, 
transplantation, uremic syndrome 
Moderate or severe liver 
disease 
Cirrhosis with Portal hypertension +/- variceal 
bleeding 
AIDS AIDS and AIDS-related complex Suggested: as defined in 
latest definition 




Physical function is registered as score/grade 0-5 of the Eastern Cooperative Oncology 
Group performance status (ECOGPS or ECOG performance status). Grade 5 is not included in 
the CRF. ECOG i  f e  egi e ed a  WHO c e e g  WHO II-III  hi  h d be egi e ed 
as ECOG, and the highest score is the score to register in the Web-CRF. Note date of ECOG 
registration, if no ECOG reports are f d i  he edica  j a  ic  f ; N  ECOG 
egi e ed   Ch e ECOG c e    PN a  If a  ECOG egi a i  da e  e ha   
h  bac  ic  f  N  ECOG egi e ed  
 
Table 4: ECOG Performance status 
Grade Explanation of activity 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours 
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours 




Current medications include medication of regular use as well as medication prescribed and 
used when necessary. Current medications are registered in selected drug groups, find out 
hich g  he d g  be g  a d ic  f  he a ia e b e  Y  a  ic  f  
several boxes if appropriate. Check drug classification for each drug you wish to register.  
 
Useful resources for drug classification: 
- www.felleskatalogen.no  





Table 5: Examples on drug classification in different drug groups 
 
Non-opioid analgesicks Asitylsalisylacid (Asprin), Fenazon, 
Paracetamol, Albyl- E 
Opioids Morphine, Oxycodone, Oxynorm, Codein, Tramadol, Ketobemidon, 
Buprenorphine, Methadone, Petidine, Hydromorphone, Fentanyl, 
Alfentanyl, Sufentanil, Remifentanil, Tapentadol, Oxynorm, Oxycontin. 
Co-analgetics  TCA2: Amitryptylin, Nortriptylin.  
SNRIs3: Venlafaksin, Duloksetin. Antiepileptica: Gabapentin, 
Caramazepin, Pregabalin, Valproat, Clonazepam. 
Anestetics: Cetamin 
Esketamin 
Corticosteroids Glucocorticoids, Betamethason (Celestone), Prednisone (Prednisone 
Intensol), Prednisolone (Predmosolon Alternova, Prednisolone), 
Triamcinolone (Aristopan Intra-Articular, Aristopan Intralesional, 
Kenalog), Methylprednisolone (Medrol, Depo-Medrol, Solu-Medrol, 
Methylprednisolone Orion), Hydrocortisone (Plenadren, Solu- Cortef), 
Cortisone (Cortisone, Cortisoneacetate )  
Antidepressants Clomipramine (Anafranil, Clomipramine), Trimipramin (Surmontil), 
Amitiptyline (Abcur, Orifarm, Sarotex), Nortiptylen (Nortren), 
Doksepin (Sinequan),  SSRIs such as Fluoxetine (Prozac, Sarafem), 
Citalopram (Celexa, Cipramil), Escitalopram (Ecitalopram Mylan and 
Teva, Cipralex, Lexapro), Paroxetine (Paxil, Pexeva, Brisdelle, 
Paroxetine, Seroxat), Sentralin ( Accord, Bluefish, HEXAL, Zoloft), 
Fluvoxamine (Fevarine), Moclobemide, Mianserine, Mirtaserine, 
Mirtaxapine, Bupropion, Venlafaksin, Reboksetine, Duloksetin, 
Vortioksetin (Brintellix)  
Antiemetics Afipran, Ondasetron (Zofran), Granisetron (Sancuso), Tropisetron 
(Navoban), Palonosetron (Aloxi), Netupotant and Palonosetron 
(Akynzeo), Scopolamine (Scopoderm), Aprepitant (Emend, Ivemend).  
Neuroleptics Levomepromazin, Perfenazin, Proklorperazin, Haloperidol, Droperidol, 
Sertindol, Ziprasidon, Lurasidon, Flupentiksol (Fluanxol), Klorprotiksen 
(Truxal), Zuklopentiksol (Cisordinol), Lokapin (Adasuvre), Clozapine 
(Clozapin, Leponex), Olanzapine, Kvetiapin (Quetiapine, Seroquel), 
Amisulprid (Solian), Lithium (Lithionit), Risperidon (Risperdel, 
Risperpolept), Aripirazol (Abilify), Palperidon (Trevicta, Xeplion). 
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Sedatives/ anxiolytics Hypnoticums, Vival, Sobril, Isofluran, Desfluran, Sevofluran, Tripental, 
Fentanyl, Alfentanil, Sufentanil, Remifentanil (Ulvita), Ketamin, 
Propofol, Nitrogen oxide, Esketamine, Bupivacaine (Marcaine), 
Lidocaine (Versatis, Xylocain), Mepivacain (Carbocain, Scandonest), 
Ropivacain, Lidocain, Articain, Capsaicin (Capsina, Qutenza), 
Alprazolam (Xanax), Diazepam (Valium), Flunitrazepam, Lorazepam 
(Ativan), Nitrazepam, Oksazepam, Trizolam, Buspiron, Hydroxyzin, 
Klometiazol, Doxysylamine, Barbital. 
Drug(s) for acid related disorders Alginate,  Antacids, H2 receptor antagonists (Cimetidin, Famotidine, 
Ranitidin), PPIs4 (Esomeprazol, Lansoprazol, Pantoprazol), Nexium, 
Somac Control 
Laxatives Laktulose, Laktitol, Movicol, Laxoberal, Toilax,  Magnesium sulphate,  
Sennaglycosides (Angiolax, granulate), Biscodyl, Rivinus oil, Paraphine, 
Bisacodyle (Dulcolax suppository), glycerol, dioxysulphosuksinate, 
laurylsulphate, Docusate (Microenema),  
Polyethyl glycol, Psyllium hydrophilic mucilloid (Metamucil), Calcium 
Polycarbophyl, Methylcellulose (Citrucel), Colace, Surfak, aloe, 
cascara, Ex.lax, senokot, dulcolax, correctol, castor oil, Fleet phosphor-
Soda. 
Antibiotics Amoxicillin, Doxycycline, Cephalexin, Ciprofloxaxin, Clindamycin, 
Metronidazole, Azithromycin, Sulfamethoxazole/ trimethoprim,  
Diuretics Chlorothiazide (Diuril), Chlorthalidone( Hydrogroton), Indapamide 
(Lozol), Hydrochlorothiazide (Hydrodiuril), Methyclothizide (Enduron), 
metolazone (Zaroxylyn, Diulo, Mykrox) 
Heart medication/ 
antihypertensives 
Statins: Atorvastatin (Liptor), Rosuvastatin (Crestor), Lovastatin 
(Advicor), Choleterol Absorption inhibitors ( Ezetimbe/ Simvastatin 
(Vytorin). Antihypertensives: Enalapril (Vasotec), captopril (Capoten), 
Lisinopril (Zestril and Prinivil), Benazepril (Lotensin), Quinapril 
(Accupril), Perindopril (Aceon), Ramipril (altace), Trandolapril (Mavik), 
Selo-zok 
Anticholinergica Bentyl, Buscopan, Levsin, Pamin 
NSAIDS1 Brufen, ibux, ibuprofen, Dicofenac, Toradol, Voltaren, Napren, Relifex, 
Celebra, Celebrex 
1NSAIDs: Non-Steroid anti-inflammatory drugs, 2TAC: Tricyclic antidepressiva , 3SNRIs: Seretonine-







Principle cancer disease and treatment 
 Note time of cancer diagnosis, month and year. 
o If month is not registered, fill inn 00 for month: e.g.; 00.2008 
 «Tick of» box for cancer type. If other, specify cancer type.  
 «Tick of» for stage of cancer disease; local, locally advanced or metastatic/ 
disseminated.   
 If e a a i  ic  f  f  ca i  several options possible. 
o Lymph nodes Cancer that have spread from other part of the body to the 
lymph nodes. 
o Peritoneum –mesentery – Cancer from other part of the body spred to 
peritoneal ligaments, mesentery and omenta.  
o Liver  Cancer that have spread from other part of the body to the the liver. 
o Lung - Cancer that have spread from other part of the body to the lungs. 
o Central nerve system  Cancer that has spread form the original (primary) 
tumor to the central nerve system (CNS).  
o Peritoneal carcinomatosis – When carcinomatosis of peritoneum or abdomen 
is described in medical journal 
o Bone When cancer cells spread from their original site to a bone. Can occur 
in any bone, occurs most common in the spine, pelvis and thigh.  
o Other Cancer spread from original site to other part of the body, e.g.; bone 
marrow, carcinomatosis of lungs or other organs, any other matastatis. If 
other, specify location of metastasis.  
 Tic  f  f  e i  a i-cancer treatment, before PN start. Several options 
possible. 
o Chemotherapy  Use of drugs to destroy cancer cells.  
o Radiotherapy  The use of high-energy X-rays or other particles to destroy 
cancer cells.  
o Surgery Removes the tumour and nearby tissue during an operation.  
16 
 
o Immunotherapy Ca ce  ea e  ha  b  he b d  a a  defe ce  
to fight cancer. Use substances made by the body or in a laboratory to 
improve or restore immune system function.  
o Targeted therapy Cancer treatment that use drugs to target specific genes, 
proteins, or the tissue environment that contributes to cancer growth and 
survival. 
o Other Hormone therapy  
 Tic  f  f  g i g a i-cancer treatment, at PN start.  Several options possible. 
 Register presence of ascites at PN start.  
Cancer type 
o Lunge Include uncontrolled growth of abnormal cells that starts off in one or both 
lungs, bronchial adenoma which starts in the mucus glands and ducts of bronchi or 
trachea and in the salivary glands. Also, bronchogenic carcinoma (malignant 
neoplasm of the lung from epithelum of bronchi or bronchiole) is included.  
o Head and neck Include hypopharyngeal cancer, laryngeal cancer, lip and oral cavity 
cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus and nasal 
cavity cancer, salivary gland cancer and brain tumours.  
o Upper gastro intestinal tract Include esophageal cancer, stomach cancer, pancreatic 
cancer, liver cancer, gallbladder cancer  
o Colorectal Include cancer from the colon, sigmoid and rectum 
o Breast Include cancer developed from breast tissue 
o Prostate Include cancer that occur in the prostate 
o Bone Include primary bone cancer, cancer that forms in cells of the bone. 
o Skin  Include uncontrolled growth of abnormal skin cells.  
o Lymphoma Include cancer that begins in infection-fighting cells of the immune 
system. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other 
parts of the body. There are two main types of lymphoma: Non Hodgkin lymphoma 
and Hodgkin lymphoma.  
o Leukaemia Include cancers that usually begin in the bone marrow and result in rise 
of numbers of white blood cells. These white blood cells are not fully developed and 
are called blasts or leukemia cells.  
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Nutritional status  
Fill in date of measurement. Fill in body weight in kg and height in cm.  
If possible, register previous weight taken 4-6 months ago, 2-3 months ago and 2 weeks-1 
month ago. If no previous weight loss is reported, but percent weight loss from a certain 
month is registered, use formula described in research manual to calculate previous weight. 
If last registered weight is registered more than 2 weeks from PN a  egi e  a  B d  
weight 2 weeks-  h ag  a d ea e B d  eigh  egi a i  b a  If b d  eigh  i  
egi e  e  ha   ee  bef e PN a  egi e  de  B d  eigh   
 
Percent weight loss and previous weight calculated by formula: 
Percent weight loss (%) = (Weight loss (kg)/Previous weight (kg)) x 100  
Previous weight (kg)= (weight loss (kg) x 100)/ percent weight loss 
 
Example previous weight: 
Percent weight loss: 16.7% 
Current weight = 50 kg 
Weight loss= 10 kg 
Previous weight = (10 kg x 100) / 16.7 = 60 kg 
➢ This formula can be used if percent weight loss is registered in medical journal and 
not previous weight.  
➢ Use registered body weight if available. 
➢  
Nutritional screening 
If PG-SGA screening is registered, fill in stage A, B or C. If NRS2002 screening is registered, fill 
in score for nutritional status, score for severity of disease and score for age. If no score is 
egi e ed  ic  f  b  f  i i g   Nutritional screening can be registered in 





Dietary registration  
Register if there was performed dietary registration of the patient. If dietary registration 




Register any diagnosis of malnutrition. Moderate protein-calorie malnutrition can be 
registered as ICD-10 diagnosis E 44 or E 44.00, SGA grade B or PG-SGA grade B. Severe 
protein- calorie malnutrition can be registered as ICD-10 diagnosis E 43 or E 43.00, SGA 
grade C or PG-SGA grade C.  If same weight as at PN start is used to calculate malnutrition 
diagnosis, register malnutrition diagnosis at PN start.  
CT-scan 
Find CT scan of level L3 vertebrae taken closest up to start PN and note date of examination 
and e a i a i  e  CT e e  L  i  f e  efe ed  a  CT abd e   CT be e  If 
MR is taken instead of CT, register this in comments with type of MR examination and date 





Symptoms are assessed using the Edmonton Symptom Assessment System (ESAS). The 
severity at the time of assessment of each symptom is rated from 0-10 on a numerical scale. 
The ca e i  bjec i e i  ega d f e e i  a d he g d a da d  f   
assessment. ESAS can be registered in an ESAS form or as scores handed out by a doctor in 
patient medical record. Both is regarded as ESAS score and should be registered in the  
Web-CRF.  
0 = symptom is absent 
10 = symptom of the worst possible severity.  
✓ Register if there is registered ESAS form at PN start 
✓ Fill in date of registration of ESAS form 
✓ Fill in numeric value for each symptom registered in ESAS form 
o Pain 
o Tiredness/ fatigue decreased energy level (but not necessarily sleepy) 
o Nausea 
o Depression blue or sad 
o Anxiety nervous or restlessness 
o Drowsiness -sleepiness 
o Appetite 
o Wellbeing Overall comfort, both physical and otherwise. 
o Shortness of breath 
o Sleep 
o Obstipation 
Biochemical blood analysis 
Fill in value of blood analysis and date of each analysis closest up to PN start. If missing, 





3) PN treatment 
Treatment start 
Register information regarding last PN treatment before final PN termination. 
✓ Register date for start of PN treatment 
✓ Tic  f  egistered Indication for use of PN 
✓ Register if there was drainage of gastric fluid. 
✓ Regi e  ai  i i  f ca e d i g PN ea e  b  ic i g ff  main care 
provider. Main care provider is the institution who are in charge of patient follow up 
of PN treatment.  
✓ Register previous PN treatment and number of times patient have been receiving PN 
treatment. 
Indication for use: 
o Gastro intestinal malfunction: Before a perforation, intestinal obstruction or 
chylothorax, high-throughput entero-cutaneous fistulas, in paralytic ileus, digestive 
haemorrhage, insufficient absorptive surface due to cancer surgery or radiation 
enteritis. 
o Insufficient oral and/or enteral intake: When oral intake is less than 60% of 
nutritional needs for more than 1-2 weeks and improvement in nutritional status 
and quality of life is foreseen. Oral mucositis that prevent enteral access. When low 
food intake is listed as indication for PN start.  
o Patients wish: When patient or relatives of patient wish is indication for start of PN 
treatment.  
o Promote tolerance for cancer treatment: When PN treatment is given so the patient 
can receive more anti-cancer treatment, or to make patient strong enough to 
receive anti-cancer treatment.  
o Other –If other indications are registered, specify in comment field 
o Short bowl syndrome If short bowl is indication for PN start, or contributes to 
insufficient oral and/ or enteral intake 





✓ Register if the patient was referred to clinical dietitian in relation to PN start and/ or PN 
follow up. 
✓ If yes, register number of consultations. 
Estimated nutritional needs: 
✓ Register if estimated energy needs were calculated  
✓ If yes, note estimated energy need in kcal/ day 
✓ Register dietary registration during PN treatment, and how many days dietary registration 
was performed.  
Parenteral nutrition  
✓ Register additional oral nutrition to PN treatment. Several options is possible 
o ONS = oral nutritional supplement (e.g  nutritional drinks)  
o Enteral nutrition = tube feeding, PEG or enteral feeding via jejunostomi.  
✓ Register additional oral supplements to PN 
✓ Register type of infusion pump 
✓ Register route of administration 
✓ Register type PN solution used 
✓ Register micronutrients added to PN solution. Register vitamins, minerals and electrolytes 
and other,  include dose given 
o If TSN  i e i ge   SVA i  registered next to PN solution this is usually the 
a da d ac age f S i  Vi a i id  a d Adda e  Thi  i  addi i  f i a i  
and trace elements necessary for nutritional solutions to make them nutritional 
complete and should always be given in PN treatment! This might not be registered 
in the medical journal: Assumed given if otherwise not specified.  
✓ Register other additions to PN solutions 
o Insulin is only registered if given directly to PN solution, not if administered in the 
regular way.  
Additional IV fluid  
✓ Register if patient were given additional IV fluid 
✓ If yes, register type of fluid given IV in addition to PN solution. Register start amount of 
additional fluid given IV in ml.  
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4) Administration of treatment plan 
Infusion 
Infusion describes how PN is given to the patient.  
✓ Register type of infusion 
✓ Register how many days a week patient received PN treatment 
Type of infusion: 
o Continuous – 24 h continuous treatment, where the non-fat bag (solution A) is infused over 
24 h not the lipid (solution B) is infused for 20 h. This is switched off for four hours prior to 
blood sampling to allow for clearance of the fat emulsion from the plasma. 
o Cyclical –When PN is infused for less than 24 h. Cyclical infusion can be given during the 
igh  a d d i g he da  If a ie   ecei e igh  i f i  ic  ff  f  c c ica  
infusion igh  If a ie  ecei e i f i  a  a ie  i e a da  ic  ff  f  c c ica  
infusion he . 
Days a week: 
o Some might receive PN treatment less than 7 days a week. If such information is registered, 
register how many days a week PN was ordinated/ given. If no such information exist only 
continuous registrations, register as 7 days a week. If breaks in registration, register as pause 
under study- a  Ad i i a i  f PN  
Dose delivered 
✓ Register start dose in kcal/day 
o If PN solution is registered and dose is registered in ml/ day, find solution folder and 
calculate kcal/ day from PN solution registered. 
o If dose is registered and delivery is registered in hours/ day, use this information to 
calculate ml/h and whether infusion was given continuous or cyclical.   
✓ Register date of adjustment, and adjusted dose in kcal/day of each adjustment. 
Delivery rate 
✓ Register if delivery rate is registered 
✓ Register delivery rate in ml/h for each adjustment registered of the delivery rate.  
Delivery rate is how fast PN solution is given. This might be reported in ml/h, or as e.g. 1970 ml 
delivered over 15 hours, which result in delivery rate of 131 ml/h.  
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Pause in PN treatment 
 Register if there have been pauses in PN treatment and how many pauses during PN 
treatment.   
A break of 14 days or less is regarded as pause in PN treatment.  A break lasting longer than 14 days 
is not regarded as a pause, but as start of a new PN treatment. 
  
5) Adverse events during PN treatment 
Adverse events during PN treatment 
✓ Regi e  ad e e e e  egi e ed d i g PN ea e  Tic  ff  e e a  ad e e e e  if 
appropriate. 
✓  Tic  ff  c e e ce f ide ad e e e e  
o If a ie  had edica  i e e i  i  e a i   ide effec  ic  ff  hich 
intervention. 
Positive observations related to PN treatment  
✓ Register positive observations related to PN ea e  Tic  ff  a ia e b e   
register other. 
✓ If other, specify.  
✓ If clinical observations from nurse please quote in text field, if registered. NB! It is not 
allowed to copy-paste from the patient medical journal. Please type in clinical observations. 
 
6) Patient characteristics during PN treatment 
Principle cancer disease and treatment during PN treatment  
✓ Register new metastases and location of these metastases during PN treatment. Several 
options possible.  
✓ Tic  f  e  a i-cancer therapy for current cancer disease since PN start. Several options 
possible.  
✓ Tic  f  e i i a ed a i-cancer therapy since PN start. Several options possible. 
✓ Register presence of ascites 




Nutritional status and symptoms 
✓ Register if body weight was registered during PN treatment 
✓ If yes, register body weight in kg, and date measurement were taken during PN treatment. 
Register body weight at different dates if registered. 
✓ Comments: If comments regarding body weight register in text field (short and to the point).    
CT-scan 
Find CT-scan of level L3 vertebrae.  
✓ Register number of CT scans taken during PN treatment 
✓ Register date of registered CT-scans or planned date of CT-scan 
✓ Register type of examination 
✓ If comments, register these in text field.  
 
Performance status 
 Register ECOG performance status registrations during PN treatment as described in 
1) At PN start.  
 If available, register several ECOG registrations during PN treatment.  
 
Symptoms 
✓ Register ESAS symptom scale as described in 1) At PN start.  
✓ If available, register several ESAS registrations during PN treatment, and date of registration 
of each ESAS form. 
 
7) Biochemical blood analysis during PN treatment  
Biochemical blood analysis 
 Fill in new values of blood analysis and date of each analysis.  





✓ Register date of death 
✓ Register where patient died. 
✓ Register date of last anti- cancer treatment  
PN termination 
 Register date of PN termination 
✓ Register reason for discontinuation of PN treatment, several options possible. Choose the 
most appropriate category for this patient. If several categories of discontinuation are 
appropriate, several options are possible. 
✓ If other reason for discontinuation, please specify. 
  
 
 
 
